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Red blood cell derived vasodilators: determination and modulation 
Juliana Garcia 
A luciferin-luciferase chemiluminescence method was used to quantify extracellular 
adenosine triphosphate (ATP) released by red blood cells (RBCs) after stimulation with 
nitroglycerin, a potent vasodilatory drug. Attenuation in the amount of ATP released from 
RBCs was observed after treatment with increasing concentrations of nitroglycerin or nitrite. 
However, RBCs exposed to nitroglycerin or nitrite for < 5 min released increased amounts of 
ATP. A mechanism of blood flow regulation through an ATP-NO/NO2" pathway is proposed. 
Nitroglycerin-derived N02" is converted within RBCs to NO, which might activate ATP 
release. In vivo, ATP will stimulate endothelial nitric oxide synthase (eNOS), increasing NO 
production and causing vasodilation. NO could diffuse into the blood stream where it is 
converted to NO2" and taken up by downstream RBCs, further increasing their ATP 
production. Thus, the original RBC-derived NO2VNO signal could be amplified both by the 
action of ATP and NO. 
Nitroglycerin was also shown to act as a "suicide substrate" for RBC glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). GAPDH reduced nitroglycerin to glyceryl dinitrates 
and NO2" using its active-site cysteines as electrons donors. This inactivation inhibited the 
bioconversion of nitroglycerin to NO2" and caused an attenuation of the drug's effect. The 
dehydrogenase activity of GAPDH was also suppressed, thereby limiting the production of 
ATP and propagation of the vasodilation signal. 
The extracellular profile of ATP-derived ADP, AMP and adenosine was additionally 
studied by LC-UV. Preliminary ESI mass spectrometric analysis of epoxyeicosatrienoic acids 
and prostacyclin, RBC vasodilators derived from arachidonic acid, was explored. 
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1. General Introduction 
1.1. Red blood cells and vasodilation 
The regulation of vascular tone and blood flow is a complex process driven 
mainly by local regulatory mechanisms at the blood vessel wall. An important regulatory 
system in localized vasodilation is the molecular crosstalk between red blood cells 
(RBCs) and endothelial cells in the microvasculature (1). It is well-established that the 
endothelium produces and releases a number of vasodilatory factors including the 
endothelial-derived relaxing factor (EDRF) that is nitric oxide (NO), adenosine, 
prostaglandins and the endothelium-derived hyperpolarizing factor (EDHF) (2). 
RBCs are responsible for the transport and delivery of oxygen to meet the 
metabolic demands of tissues. O2 gradients act as the main regulator of blood flow in the 
microvasculature (3-6). Recent research has shown that RBCs are also responsible for the 
release of blood flow regulators including adenosine triphosphate (ATP) under 
physiological stress (7-9). Pharmacological agents that treat cardiovascular diseases in 
which vasodilation is compromised, such as myocardial ischemia (angina), modify the 
normal patterns of this local regulation of blood flow. A focus of this thesis is the export 
of ATP and others vasodilators from isolated human RBCs. The results obtained 
contribute to our understanding of the role of RBCs in the localized regulation of blood 
flow in the microvasculature. 
1.1.1. Red blood cell properties 
Mammalian RBCs are small, flexible, biconcave discs consisting of a plasma 
membrane and a few associated proteins (10). RBCs are produced and matured in the 
bone marrow, and are known as reticulocytes prior to being released into the blood 
stream. In humans, RBCs are the smallest cells with an average diameter of 8 u.m and a 
life span of 120 days (1). Mature RBCs lack nuclei, mitochondria, and other specialized 
organelles, so they are unable to synthesize proteins. Hemoglobin (Hb), at an intracellular 
concentration of 5 mM, is the major component of RBCs. Its primary role is the transport 
of O2 from the lungs to the muscles and the transport of CO2 from the muscles to the 
lungs to be exhaled. Historically, RBCs had been characterized as "dead" cells, or mere 
Hb-filled receptacles with the sole function of O2 transport. However, recent research has 
shown that RBCs carry out more than O2 transport; they are actively involved in 
controlling the dilation of blood vessels. Identified mechanisms by which RBCs 
participate in vasodilation require 02-regulated binding and bioactivation of NO by Hb 
and ATP release (10-14). 
1.1.2. Nitric oxide and vasodilation 
In 1998 Furchgott, Ignarro and Murad were awarded the Nobel Prize in Medicine 
"for their discoveries concerning nitric oxide as a signaling molecule in the 
cardiovascular system" (15). They identified NO as the endothelium-derived relaxing 
2 
factor (EDRF), a potent vasodilator formed on the hydrolysis of Z-arginine to Z-citrulline 
mediated by the enzymatic action of nitric oxide synthase (NOS) in the presence of 
oxygen (2) (Figure 1.1). In the vasculature, endothelial nitric oxide syntahse (eNOS) is 
the isoform responsible for the production of NO that triggers the signaling cascade 







/ \ ' 








0 2 H20 
OH 








Figure 1.1 Enzymatic n i t r ic oxide formation. Oxidation of /.-arginine to L-citrulline with formation o f 
NO by nitric oxide synthase (NOS). Adapted from (16). 
NO has a short half-life (5 s) under physiological conditions (17). Possible 
mechanisms of NO scavenging in blood are its oxidation by O2 to generate nitrite (NO2), 
which is catalyzed by ceruloplasmin (18), and its reactions with Hb (19, 20). These 
mechanisms act to control vascular tone by reducing the smooth muscle exposure to NO, 
as proposed by Stamler and co-workers (21). Currently, some research groups consider 
nitrite to be the major storage pool of NO vasoactivity in blood (13, 22). 
Figure 1.2 Signaling cascade originated by the formation of NO. NO, synthesized from L-arginine in 
the endothelium by eNOS activity, stimulates guanylate cyclase (GC) leading to increased cyclic guanosine 
monophosphate (cGMP) levels. These activate protein kinase A (PK.A), which results in smooth muscle 
relaxation by reducing the intracellular calcium concentration. Adapted from (2). 
1.1.3. Nitrite in vasodilation 
Nitrite salts were used in antiquity by different cultures mainly as a food 
preservative (23). In the early 1800s. industrial exploitation of sodium nitrite focused on 
the manufacture of dyes, pharmaceuticals, anticorrosives and meat preservatives. Its 
physiological and biological relevance became more evident around 1860, when studies 
on the reactivity of nitrite with Hb were described by Hermann (24). 
Diet represents the principal source of nitrite in mammals. In the gastric system, 
nitrite (NO2) is generated by the reduction of nitrate, which is abundant in vegetables and 
drinking water (23). Nitrite is accumulated in saliva and partially reduced to NO and 
4 
oxygenase-1 (25). Gladwin and coworkers demonstrated that nitrite infusion into the 
human forearm increases blood flow, and they hypothesize that vasodilation is mediated 
through the reduction of nitrite to NO by deoxyHb (13). They also proposed that nitrite is 
the largest storage pool of NO in the blood stream (13). However, no evidence exists that 
nitrite donors activate NO release from RBCs. Moreover, Li and co-workers recently 
showed that NO production from nitrite occurs mainly in tissues and not in blood (26), 
suggesting that a molecular messenger other than NO is responsible for RBC-derived 
vasoactivity. 
1.1.4 Epoxieicosatrienoic acids 
Epoxyeicosatrienoic acids (EETs) are cytochrome P450 metabolites of 
arachidonic acid with an important role in the mediation of vasodilation in muscle tissue. 
Four structural isomers are physiologically available, and 11,12-EET and 14,15-EET are 
the most abundant (Figure 1.4). 11,12-EET is suggested to be the endothelial-derived 
hyperpolarization factor (EDHF) (27-29) responsible for modulation of relaxation of 
vascular smooth muscle. EETs are involved in other signaling cascades that control 
inflammation and in regulating cell proliferation and migration processes (30). 
Both RBCs (Figure 1.5) (31) and endothelial cells (32) produce and release EETs. 
These messengers cause vasodilation by activation of calcium-dependent phosphate 
channels, reducing the intracellular calcium concentration in smooth muscle and 







Figure 1.6 EET-derived vasoactivity. Shear stress and reduced oxygen levels activate membrane G-
proteins which stimulate phospholipase A2 (PLA2), causing the release of arachidonic acid (AA) from 
membrane phospholipids. The epoxigenase action of cytochrome P450 converts AA to EETs, which are 
released from RBCs and endothelial cells and activate calcium channels in the membrane of smooth 
muscle cells, reducing calcium influx and hyperpolarizing the cell. Adapted from (2). 
1.1.5 Prostaglandins 
The endothelium is the major source of prostaglandins in the vasculature (2). 
These are a family of molecules derived from arachidonic acid (AA) via the action of 
cyclooxygenases (COX-1 and COX-2). Prostaglandins are involved mainly in 
inflammatory processes and cardiovascular tone control. Prostaglandin h (PGI2X which is 
also known as prostacyclin (Figure 1.7a), is involved in the regulation of muscle blood 
flow. Prostacyclin causes vasorelaxation predominantly via the adenylyl cyclase/cyclic-
AMP transduction system (34) (Figure 1.7b). 
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Figure 1.7 (a) Structure of prostacyclin, (b) PGI2-derived vasoactivity. Shear stress and reduced 0 2 
levels activate membrane G-proteins which in turn activate phospholipase A2 (PLA2), resulting in the 
transformation of membrane phospholipids into arachidonic acid (AA). The action of COX on AA 
generates PGI2, which increases the levels of cyclic adenosine monophosphate (cAMP) and decreases 
phospholipase C (PLC) activity. The net result is a reduction in intracellular calcium which leads to 
smooth muscle relaxation. Adapted from (2). 
1.1.6 Adenosine triphosphate 
ATP is one of the most ubiquitous molecules in nature. It participates in many 
neurotransmission metabolic pathways as the energy currency of the cell and acts as the 
chemical energy storage for intracellular processes (35). ATP is also involved in 
signaling by targeting membrane purinergic receptors (36). Structurally, the molecule is 
composed of an adenosine unit, a purine nucleoside formed by adenine and ribose, 
covalently bond to three inorganic phosphate groups (Figure 1.8): 
9 
Figure 1.8 Structure of adenosine triphosphate (ATP) 
RBCs are known to release ATP at low pH or low oxygen concentration and in 
response to mechanical deformation (8, 9, 37) (Figure 1.9). This release of ATP is 
believed to act as a response to high oxygen demand in the microvasculature and 
provides evidence for RBC control over vascular tone (14, 38). ATP is known to exert a 
very powerful vasodilatory response in skeletal muscle, lung, and brain (39-42), although 
the mechanism of action is a matter of much debate. It has been demonstrated that ATP 
is the RBC link to NO synthesis in rabbit lung (43). 
RBC-derived ATP activates the NO signaling cascade in endothelial cells by 
yielding adenosine and stimulates the membrane heterotrimeric guanine nucleotide-







Figure 1.9 RBC-derived ATP increases production of vasodilators in endothelial cells. Shear stress, 
reduced oxygen levels and low pH cause the release of ATP from the RBC. ATP is converted by ecto-5'-
nucleotidase (e5'-n) into adenosine, a potent vasodilator that acts through the NO signaling cascade. Other 
mechanisms are the activation of the PGI2 and EET signaling cascades by activating membrane 
heterotrimeric guanine nucleotide-binding (G) protein, which then activates PLA2 stimulating the 
production of arachidonic acids from membrane phospholipids. Adapted from (2). 
1.1.7 Glyceraldehyde 3-phosphate dehydrogenase 
One of the major metabolic sources of ATP in mammalian cells is glycolysis. The 
glycolytic pathway is central in energy metabolism, providing a significant portion of the 
celFs energy requirements by converting glucose to pyruvate. This is accompanied by the 
generation of two moles of ATP (35), as shown in Reaction 1.1. 
11 
1.2 Nitroglycerin 
The Heart Disease and Stroke 2008 Update Statistics compiled by the American 
Heart Association lists ischemic heart disease as one of the main causes of death in North 
America (49). Since 1879. the standard treatment for angina, the most common symptom 
of this condition, has been the administration of nitroglycerin (50) (Figure 1.11). Angina 
is the chest pain experienced by patients with ischemic conditions due to the lack of 
oxygen supply to the heart and the inability to increase coronary blood flow. 
Nitroglycerin acts as a potent vasodilator, causing a rapid increase in myocardial oxygen 
supply and relief of pain associated with angina. 
O2N ^ ~ . ^ - ^ NO2 
o ^Y o 
°\ 
N02 
Figure 1.11 Nitroglycerin structure 
1.2.1 Pharmacology and pharmacokinetics 
The metabolism of nitroglycerin leads to the formation of NO (51), which can 
exert an intense vasodilatory response (Section 1.1.2). The mechanism by which 
nitroglycerin yields NO is still not entirely understood (Figure 1.12) but there is strong 
evidence for an enzyme-dependent process. To date many enzyme candidates have been 
proposed (Section 1.2.2). 
13 
Nitroglycerin can be administered through several routes: sublingual, buccal, oral, 
transdermal, and intravenous. Patches, sprays, and rapidly dissolving tablets are widely 
available comercially. Doses of 0.2-0.8 mg can be administered orally with 5 minute 
intervals between doses until pain disappearance. Patches containing 5.0 mg are designed 
to release small doses over 24 hours. Physiological effects are experienced within 3 to 5 
minutes of nitroglycerin adminstration. 
Nitroglycerin undergoes rapid clearance by the liver, lungs and blood, and most 
denitrated metabolites are excreted via the kidney (50). Metabolic half-lives in whole 
blood of 3-5 minutes, in plasma ~52 minutes and ~3 minutes in RBCs have been 
reported (52). These values suggest that most of the metabolic processing of nitroglycerin 
in whole blood is performed by RBCs. 
0,N 
N02 
1,2 glyceryl dinitrate 
NO 
nitroglycerin 02N 
1,3 glyceryl dinitrate 
Figure 1.12 Nitric oxide derived from nitroglycerin. Activation processes and mediators are still under 




The vasodilatory potential of nitroglycerin and related organic nitrates is related 
to their ability to yield NO (50). Few nonenzymatic mechanisms have been reported for 
nitroglycerin bioactvation. Notably, Ignarro and Gruetter proposed -NO2 transfer from 







2 S-nitrocysteine cystine 
Figure 1.13 Bioactivation of nitroglycerin by cysteine. Nitroglycerin (RON02) reacts with cysteine 
(RSH) to generate 1,2- or 1.3-glyceryl dinitrate and S-nitrocysteine. Two S-nitrocysteine molecules react 
to form cystine and NO. Adapted from (54). 
Enzymatic bioactivation of nitroglycerin by many candidate enzymes has been 
proposed and there is still much debate about their relative efficiencies. These candidates 
are discussed in the following sections. 
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1.2.2.1 Glutathione S-transferases 
Glutathione S-transferases (GSTs) are a family of cytosolic and mitochondrial 
proteins with different isoforms. Detoxification of endogenous compounds is one of their 
many functions and GSTs were among the earliest candidates postulated as nitroglycerin 
bioactivators (55, 56). Bioactivation of nitroglycerin (RNO2) by GST requires 2 
molecules of glutathione (GSH) with the formation of nitrous acid (HNO2) (pKa = 3.4) 
(57) as shown in Reactions 1.2 and 1.3. 
GSH + RONO2 -> [GS-NO2] + ROH (1.2) 
[GS-NO2] + GSH -* GSSG + HN0 2 (1.3) 
2HN02 -» NO + H 2 0 + N0 2 (1.4) 
Disproportionation of nitrous acid in an aqueous environment (Reaction 1.4) (57) 
leads to the formation of NO and NO2, which could induce a vasodilatory response in 
vascular tissue. Research by Kurz and coworkers found a linear correlation between GST 
activity and NO2" production when using nitroglycerin as a substrate for the enzyme (58). 
Reaction 1.2 involves -NO2 transfer to a thiol as in Figure 1.13. However reaction of a 
free thiol and a m'trothiol yields HNO2 as an intermediate (Reaction 1.3) vs the direct NO 
generation proposed in Figure 1.13 for reaction of two nitrothiols. 
16 
1.2.2.2 Hemoglobin 
Bioconversion of nitroglycerin in the vascular system has been extensively 
discussed since this process has been suggested to be both endothelial-dependent (59) and 
independent (50). At the same time, it has been reported that nitroglycerin is relatively 
stable in plasma and it is poorly metabolized by human serum albumin (60). Importantly, 
in plasma, nitroglycerin has a half-life (~52 min) that surpasses the time frame (3-5 min) 
in which physiological effects are experienced (52). Thus, RBC-associated proteins are 
suitable candidates for nitroglycerin bioactivation in whole blood. 
As mentioned in Section 1.1.1, Hb is the most abundant protein in RBCs. Its main 
function is the transport of O2 and C02 to and from tissues. RBCs are known to 
concentrate nitrite in the vasculature, and the nitrite reductase activity of deoxyHb has 
been proposed to give rise to NO vasoactivity in these cells (20). The conversion of 
deoxyHb to methemoglobin (metHb) via reaction with NO2" suggests the potential role 
of deoxyHb as a nitroglycerin activator. Bennett and coworkers spectrometrically 
followed the interaction of deoxyHb and deoxymyoglobin with nitroglycerin and showed 
that it led to the preferential formation of 1,2-glyceryl dinitrate and nitrite (61). They 
proposed heme-mediated reductive denitrosation with a 2:1 stoichiometry: 
2 Fe"(heme) + RONO2 + H+ -* 2 Fem(heme) + ROH + N02" (1.5) 
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1.2.2.3 Cytochromes P450 
Cytochromes P450 (CYP450) are a superfamily of hemoproteins involved in 
electron transfer, steroid biosynthesis, and xenobiotic metabolism (62). The most 
common reaction catalyzed by this enzyme family is the monooxygenation of organic 
substrates. Most CYP450 are found in hepatic cells, and are considered the front-line 
defense against drugs and toxins artificially introduced to the cell. This is why CYP450s 
were considered as potential nitroglycerin activators. Servant and co-workers found 
evidence for nitroglycerin biotransformation by hepatic CYP450 since they detected the 
nitrosyl-heme CYP450-Fe(II)-NO complex spectroscopically (63). Later, McDonald and 
Bennett showed that CYP450 transforms nitroglycerin to glyceryl dinitrate derivates, 
with a preference for the 1,3- isomer (64). Isoforms of CYP450 in human heart blood 
vessels showed the ability to convert isosorbide dinitrate, an organic nitrate related to 
nitroglycerin, to NO (65). Associated with CYP450, cytocrome P450 reductase (CPR) 
has also been suggested as an important player in the bioactivation mechanisms of 
organic nitrates (66). The CPR-CYP450 nitroglycerin activation complex involves the 
two enzymes in different stages. Initially CPR reduces nitroglycerin (RONO2) to an 
organic nitrite (RONO), following by quick hydrolysis to HNO2 in a thiol-free 
environment. The nitrite reductase activity of CYP450 then catalyzes the conversion of 
HNO2 to NO. If thiol groups are available, either NO or nitrosothiols (R'SNO) can be 
formed (Figure 1.14) (66). 
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CPR 
RONO, + NADPH —> RONO + NADP+ + H,0 
no R'SH With FTSH 
RONO + H,0 —* ROH + HNO, 
CYP450 
HNO, + H+—> NO + H,0 
2RONO + 2R'SH —> 2NO + 2ROH + R'SSR' 
RONO + R'SH —> ROH + R'SNO 
Figure 1.14 Nitroglycerin bioactivation by CPR-CYP450. Nitroglycerin (RON02) is reduced to an 
orgnic nitrite (RONO) that hydrolyzes to nitrous acid. The latter is catalytically converted to NO by 
CYP450. In the presence of thiols, RONO yields either NO or nitrosothiols (R'SNO). Adapted from (66). 
1.2.2.4 Xanthine oxidase 
Xanthine oxidase is a molybdoflavoprotein abundant in certain mammalian cells, 
and it has been implicated in nitrate to nitrite reduction (67, 68). In addition to 
molybdenum and FAD, it contains two iron-sulphur redox centres. It has been reported 
that xanthine oxidase can catalyze the reductive denitrosation of organic nitrates to yield 
N02" under anaerobic conditions (69, 70). A xanthine oxidase-mediated mechanism for 
nitroglycerin and isosorbide dinitrate bioactivation was proposed by Li and coworkers, 
and involves initial oxygen transfer from the substrate (RONO2) to the reduced enzyme 
(Ered). Subsequent reaction of RONO with R'SH gives R'SNO (Reactions 1.6 - 1.7) (71), 
which can donate NO. 
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Ered + RON02 + 2H+ -> R-O-NO + HzO + E„x (1.6) 
R-O-NO + R'SH -> R-OH + R'SNO (1.7) 
1.2.2.5 Mitochondrial aldehyde dehydrogenase (ALDH2) 
ALDH2 is a homotetramer (56.4 kDa per subunit) responsible for the conversion 
of acetaldehyde to acetic acid (72), which is important in alcohol metabolism. There are 
two major aldehyde dehydrogenase isozymes: cytosolic (ALDH1) and mitochondrial 
(ALDH2). In -50% of the Asian population ALDH2 is not present, this being a possible 
cause of high rates of alcohol intoxication and low alcohol dependence present in this 
population (72). In 2002, Chen et al. identified ALDH2 as a major enzyme responsible 
for nitroglycerin bioactivation. They demonstrated both in vitro and in vivo that the 
nitrate reductase activity of ALDH2 specifically catalyzes the formation of 1,2-glyceryl 
dinitrate and nitrite from nitroglycerin, leading to relaxation of vascular smooth muscle 
(73). The overall reaction proposed for nitroglycerin activation by ALDH2 is shown in 
Figure 1.15. 
+ ALDH2red s-
nitroglycerin 1,2-glyceryl dinitrate 
Figure 1.15 Biocativation of nitroglycerin by mitochondrial aldehyde dehydrogenase. Nitroglycerin is 
activated by the reduced form of mitochondrial aldehyde dehydrogenase (ALDH2,ed), causing its oxidation 
(ALDH2„0 and generating 1.2-glyceryl dinitrate and N 0 2 \ Adapted from (59). 
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Human ALDH2 possesses three consecutive cysteine residues in its sequence, 
active-site Cys302 and adjacent Cys301 and Cys303. Two of these cysteines form an 
intramolecular disulfide bond on reductive denitrosation of nitroglycerin with NO2" 
release, as shown in Scheme 1.1. The intramolecular disulfide bond in ALDH2 has been 
characterized by mass spectrometry (74), and causes inactivation of the enzyme by 
oxidazing the active-site Cys302. Inactivation of ALDH2 has been proposed for the 
development of nitrate tolerance in patients under nitroglycerin treatment (59), which will 
be discussed in Section 1.2.3. 
ALDH2 SH + RON02 *~ t A L D H 2 | S-N0> + R 0 H 
SH 
ALDH2 s + N Q 2 
Scheme 1.1 Nitroglycerin bioactivation by ALDH2. The transfer of-N02 from nitroglycerin to one of 
the thiols of ALDH2 produces glyceryl dinitrate (ROH) and a Cys-N02 moiety that reacts with an adjacent 
free thiol. This results in a disulfide bond formation (S-S) and release of NO?". Adapted from (59). 
1.2.2.6 Glyceraldehyde-3-phosphate dehydrogenase 
Structural homology between ALDH2 and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) suggests that the latter could be involved in nitroglycerin 
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bioactivation in the vasculature. In addition to dehydrogenase activity, GAPDH and 
ALDH2 share the possession of multiple free cysteine residues. The GAPDH monomer 
has four cysteines: active-site Cysl49 and neighboring Cysl53, as well as Cys244 and 
Cys281. The architecture of the active site suggests that nitroglycerin could interact with 
GAPDH in a similar manner as it does with ALDH2 (Scheme 1.1). 
As discussed in Section 1.1.6. GAPDH is a key enzyme in the glycolytic pathway. 
It catalyzes the conversion of glyceraldehydes-3-phosphate to D-glycerate-1,3-
bisphosphate, and the latter donates a phosphate group to adenosine diphosphate (ADP) 
yielding ATP in a reaction catalyzed by phosphoglycerate kinase (PGK) (Figure 1.16) 
(35). GAPDH is highly concentrated in RBCs which exhibit high glycolytic metabolism 
(47). Inhibition of GAPDH would result in a substantial decrease in ATP production 
which may affect ATP release from the RBCs. Diminished ATP-mediated stimulation of 
endothelial nitric oxide synthase (eNOS) would in turn suppress relaxation of the smooth 
muscle due to decreased EDRF/NO production (Figure 1.9). Thus, inhibition of GAPDH 
by nitroglycerin could contribute to nitrate tolerance by two mechanisms as discussed 
further in Chapter 4 of this thesis. 
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Figure 1.16 Role of GAPDH in glycolysis and ATP production. (35). 
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Table 1.1 summarizes the published catalytic parameters in enzymatic nitroglycerin 
bioactivation. 
Table 1.1 Catalytic parameters and products reported in enzymatic bioactivation of 
nitroglycerin 
Enzyme 























































1.2.3 Nitrate tolerance 
Despite the efficacy of nitroglycerin in the treatment of ischemia, its chronic 
effects are rapidly blunted. This phenomenon is known as nitrate tolerance. Tolerance is 
not related to the pharmacokinetics of the drug, since this remains unaltered during 
chronic nitroglycerin exposure (76). Thus, factors such as reduced absorption, accelerated 
metabolism or excretion of nitrates and related metabolites are unlikely to play a role in 
the development of tolerance. 
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Loss of vascular bioactivation of nitroglycerin seems to play an important role in 
the development of nitrate tolerance. The classical mechanism proposed by Needleman 
points to the decreased availability of sulfhydryl groups (77). The Needleman hypothesis 
suggests a "vascular nitrate receptor" that contains -SH groups that interact with organic 
nitrates to release nitrite and induce vasodilation. This hypothesis has evolved to include 
inhibitory mechanisms in which disulfide bonds are formed in the active sites of 
enzymes, such as ALDH2 (Scheme 1.1) and GAPDH. Research aiming to restore the 
vasodilation effects of nitroglycerin by reducing the disulfide bond in ALDH2 has 
strengthened this hypothesis by demonstrating that enzymatic activity is recovered upon 
treatment with different reductants (59). For clinical applications, the use of reducing 
agents such as dithiothreitol (DTT) or TCEP is not viable, therefore regeneration of the 
nitroglycerin-induced vasodilatory effect must await the recovery of the free sulfhydryl 
groups by the reductase activity of thioredoxins (78, 79), glutaredoxins (80) and lipoic 
acid (81), or the synthesis of new enzymes with unaltered -SH functions (82). The latter 
could explain why drug free periods of more than eight hours allow tolerant patients to 
regain nitrite reactivity to a new dose of nitroglycerin (83). 
The presence of oxidative stress in the vasculature has also been suggested as a 
possible cause of nitrate tolerance (84). Exposure to nitroglycerin increases the activity or 
the expression of angiotensin II, a vasoconstrictor oligopeptide, which elevates vascular 
production of the superoxide anion (CV") leading to enhanced degradation of circulating 
nitric oxide to a less potent vasodilator (ONOO) (82). 
Nitrite-induced counter regulation is another phenomenon that has been linked to 
the development of nitreate tolerance, mostly in chronic exposure to nitroglycerin. An 
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example is the case of industrial munitions workers who developed ischemic heart 
conditions after retirement and their symptoms were relieved by treatment with 
nitroglycerin and/or return to industrial exposure (85). Additionally, alterations of 
metabolic or enzymatic activities have been proposed as an alternate explanation for 
nitrate tolerance and cross tolerance (80, 86). Increases in hormonal vasoactive agents 
such as catecholamine and rennin are not consistently reported with the development of 
tolerance. However, changes in the expression of mRNA of several genes present in 
blood vessels upon nitroglycerin infusion have been described in the past (87). 
1.3 Scope and outline of thesis 
The work performed for this thesis focused on the characterization of the effects 
of different vasodilators, both endogenous and exogenous, on RBCs and the possible 
vasodilatory chemical signaling originating from these cells. The results contribute to the 
elucidation of the role of RBCs in the regulation of blood flow at the microvascular level. 
Chapter 2 presents an adaptation of the well documented luciferin-luciferase 
chemiluminescence assay in microplate-reader format for the measurement of ATP 
released from human RBCs. Also, the use of HPLC to survey the ribonucleotide profile 
arising from RBCs was evaluated. 
In Chapter 3, the effects of nitroglycerin and nitrite on ATP release from human 
RBCs are compared. The changes in the ATP levels induced by time of exposure to these 
compounds as well as the effects of varying their concentrations at a fixed time are 
presented. ATP levels were measured by the chemiluminescent method described in 
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Chapter 2. Based on the results obtained, a novel mechanism is proposed to explain the 
role of RBC-derived ATP in the propagation of a vasodilation signal. 
An extended version of this chapter, with additional work performed by the other 
co-authors, was submitted on February 28, 2009 for publication to Nature Medicine as a 
letter under the title "Nitrite and nitroglycerin induce rapid release of the vasodilator 
ATP from erythrocytes: Evidence for a NO2/ATP feedback signaling pathway in blood-
flow regulation", authors: Juliana I. Garcia, Amedea B. Seabra, Renee Kennedy, and Ann 
M. English. 
Chapter 4 describes the effects of nitroglycerin on the glycolytic activity of the 
enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). GAPDH activity was 
measured spectrophotometrically and the possible relevance of results to reversible 
nitrate tolerance is discussed. 
Chapter 5 presents preliminary results on the development of a method for the 
detection and quantitation in blood plasma of the arachidonic-acid derived vasodilators, 
epoxyeicosatrienoic acids (EETs) and prostacyclin (PGI2). Overall conclusions and 
suggestions for future studies are presented in Chapter 6. 
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2. Measurement of human RBC extracellular ATP 
2.1 Introduction 
The most commonly used methods for ATP determination in blood are 
chromatography and the luciferin-luciferase bioluminescence assay. Chromatographic 
methods are more often used on blood plasma, lysed cells and treated or extracted 
samples, since co-elution and interference from other substances are common in more 
complex systems. The luciferin-luciferase assay is the method used for real time ATP 
estimation, such as the measurement of release rates from cells (88). It is also more 
convenient and commonly used on untreated samples. 
The term "bioluminescence" was defined by Newton Harvey in 1916 to describe 
the naturally occurring phenomenon in which living organisms emit 'cold' light 
(luminescence) (89). Bioluminescence is present in many organisms in nature, and it has 
been extensively studied in bacteria, Crustacea and fireflies (Figure 2.1). In 1885, the 
physiologist Raphael Dubois described the reaction that generated this light emission by 
producing a luminescent solution when dissolving ground up abdomens of the 
Pyrophores beetle in cold water (90). Dubois called luciferin and luciferase the two 
interacting substances responsible for the luminescent effect. Subsequently, Harvey 
demonstrated the occurrence of this same reaction on the tail of fireflies (91). Almost 
thirty years later, McElroy reported the dependency of this reaction on the presence of 
ATP (92) and Mg2+ (93). 
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(OxL) (Reactions 2.1 - 2.3). The luciferin-lucifererase reaction has the highest known 
quantum yield of any bioluminescence reaction, with a quantum yield of ~1 (96), 
indicating that nearly one photon of light is emitted for every luciferin molecule oxidized. 
E + LH2 + ATP + Mg2+ -> E»LH2-AMP + PPi + Mg2+ (2.1) 
E'LH2-AMP + 0 2 -» E'OxL* + AMP + C0 2 (2.2) 
E»OxL* -* E»OxL + hv (2.3) 
























Figure 2.3 Mechanism of bioiuminescent oxidation of firefly luciferin catalyzed by firefly Suciferase. 
Most likely D-luciferin binds as the dianion to luciferase. In the presence of ATP and Mg2+, luciferin is 
converted to an adenylate, yielding pyrophosphate (PPi). Oxygenation of the adenylate in the presence of 
air generates the peroxide intermediate A. This is converted to the dioxietanone intermediate B after 
releasing AMP. The decomposition of intermediate B produces an excited state of oxyluciferin CI 
(monoanion) or dianion C2. To reach the ground state CI emits red light {Xmas 615 nm), and C2 emits 
yellow-green light (Xmax 560 nm). Adapted from (94. 95). 
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Firefly luciferase is composed of a single 62 kDa polypeptide of 550 amino acids 
and is active in the monomeric form. The crystalline form of firefly luciferase was 
reported by Green and McElroy in 1956 (97). Later studies on the crystal structure of the 
enzyme led to the characterization of the active site when a highly conserved sequence 
was found near the C-terminal of three families of related enzymes: firefly luciferase, 
acyl-CoA ligases and peptide synthetases (98). 
Firefly luciferin crystallizes as microscopic needles when purified and exhibits 
fluorescence. The enzyme shows maximum absorption at 560 nm in acidic and 615 nm in 
basic solutions (94) (Figure 2.4). A molar extinction coefficient of 18.200 cm^M"' was 
determined at 328 nm (99). 
5 5 0
 600 850 700 
Wavefength (nm) 
Figure 2.4 pH-dependent spectrophotometries! changes of firefly luciferin. The common yellow-green 
luminescence of luciferin at pH 7.1 changes to red in acidic media (pH 5.4). Adapted from (100). 
The luciferin-luciferase bioluminescence assay has been widely studied and 
applied (8, 37, 101-103). The goal here was to adapt the method to our experimental 
needs and to bench-mark the parameters of re-suspended RBCs for the experiments 
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presented in this thesis. Linearity of the calibration curve and limit of detection of the 
method were determined. Also, the total extracellular ribonucleotide profile arising from 
RBCs was examined by HPLC. 
2.2 Materials and methods 
2.2.1 Materials 
Blood was collected in standard 4-mL Vacutainer® heparinized tubes (BD, 
Franklin Lakes, NJ). KC1, MgCl2 methanol (HPLC grade) were purchased from Fisher 
Scientific (Pittsburgh, PA). CaCI2 and MgS04 were purchased from ACP Chemicals 
(Montreal, QC). NaCl, tris(hydroxymethyl)aminomethane and dextrose were purchased 
from Bioshop (Burlington, ON). Sucrose was purchased from Anachemia (Lachine, QC). 
Distilled water was purified in a Milli-Q Simplicity 185, Millipore (Billerica, MA), and 
Ultrafree®-0.5 centrifugal filter Units, 10 kDa cut-off ultrafiltration membranes were 
purchased from the same supplier. Bovine serum albumin, ATP, firefly lantern extract, 
HEPES, EGTA, KH2P04, K2HP04-3H20 and NaN02 were purchased from Sigma-
Aldrich (St. Louis, MO). White 96-well plates and UV/Vis transparent lids were 
purchased from Corning (Corning, NY). Nitrogen gas (ultra high purity) was purchased 
from Praxair (Danbury, CT). HPLC analyses were carried out with an 1100 Agilent 
HPLC system using a Hypersil ODS C18RP column (Agilent Technologies. Santa Clara, 
CA). Physiological salt solution (PSS) was prepared using the following materials: in M, 
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0.0047 KC1, 0.0020 CaCl2, 0.0012 MgS04, 0.1405 NaCl, 0.0210 
tris(hydroxymethyl)aminomethane, 0.0111 £>-glucose with 0.5% w/v bovine serum 
albumin, pH adjusted to 7.4. Sucrose buffer was prepared as follows: in M, 0.321 
sucrose, 0.032 HEPES, 0.003 EGTA, 0.006 MgCl2, pH adjusted to 7.4. 
2.2.2 Preparation of red blood cells 
All procedures involving the collection of human blood samples were in 
accordance with the Concordia University Ethics Guidelines. After their informed written 
consent was obtained, blood was collected from healthy female volunteers (aged between 
20-35 years) by venipuncture into the heparinized tubes. Within two hours of collection, 
the blood was centrifuged at 5,000 rpm at 4 °C for 10 min. The plasma was collected by 
aspiration and stored at -80 °C. The buffy coat was also collected by aspiration and 
discarded. Packed RBCs were resuspended and washed three times in PSS. 
2.2.3 Measurement of ATP by chemiSuminescence 
From a stock solution of 2.5 mM ATP in PSS, ATP standards ranging from 10 
nM to 39.1 |aM ATP were prepared in PSS. The luciferin-Iuciferase assay solution used 
to measure ATP by chemiluminescence was prepared by dissolving 13.3 mg of crushed 
firefly extract in 10.0 mL of Milli-Q water. Chemiluminescence proportional to the ATP 
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in the sample was measured using a Wallac Victor 1420 multilabel plate reader 
(PerkinElmer, Waltham MA). Background emission of 100 uL of the luciferin-luciferase 
assay solution in a white 96-well plate was recorded, and immediately following mixing 
with 100 jiL of ATP standard, the emission was measured. Following background 
correction, double-log plots of emission versus [ATP] yielded a linear standard curve 
over 5 nM - 20 \iM. To measure sample ATP levels, 100 uL of RBCs at different Hct 
values were added to 100 uL of the blanked assay solution, the light emission was 
recorded, and ATP concentrations were determined using the ATP standard curve. 
2.2.4 Chromatographic determination of ATP and its metabolites 
ATP and metabolites were identified using an 1100 Agilent HPLC consisting of a 
quaternary gradient pump, a variable wavelength detector and a solvent degasser. 
Separation was achieved with a Hypersil (5-|im particles) ODS C18RP column (100x4.6 
mm). Separation of ATP and its metabolites was performed as described previously by 
Coolen et al. (104). Briefly, a gradient of 50 mM phosphate buffer (pH 6.0) (solvent A) 
and 100% methanol (solvent B) at a flow rate of 0.6 mL/min was used as the mobile 
phase. The analytes were eluted using the following linear gradient: 100% A over 2 min; 
100-87.5 % A over 10 min, 87.5% A for 12 min; 87.5-100% A over 17 min and 100% A 
over 19 min for re-equilibration of the column prior to the next sample injection. RBCs 
were prepared as described in Section 2.2.2, resuspended at 10% Hct in sucrose buffer at 
4 °C for 2 h, centrifuged at 5,000 rpm at 4 °C for 5 min, and 200 (iL of supernatant was 
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loaded into a preconditioned Ultrafree®-0.5 cell with a 10-kDa cut-off ultrafiltration 
membrane (Millipore, Billerica, MA). The sample was centrifuged at 12,000 x g at 4 °C 
for 10 min. The ultrafiltrate (50 p.L) was diluted into 200 |iL of mobile phase A and 25 
|iL of this sample was injected into a sample vial for HPLC analysis. The HPLC 
autosampler temperature was set at 4 °C, and the column was kept at 20 °C. 
2.3 Results and discussion 
2.3.1 Chemiluminescence 
Since the luciferin-luciferase reaction is affected by the presence of oxygen (94), 
chemiluminescence was measured in 96-well plates covered with a UV/Vis transparent 
lid. This also served to avoid biological contamination of the plate reader. Calibration 
curves were generated by plotting the logarithm of the chemiluminescence intensities (1) 
vs the logarithm of the ATP concentration of the standards. All measurements were 
performed using the luciferin-luciferase assay solution (Section 2.2.3). Acceptable 
linearity and reproducibility were obtained for the calibration curve averaged over 15 
independent measurements of ATP standards in the range of 9.54 nM to 39.1 jlM. The 
equation obtained was log I = 0.81 (± 0.06) log[ATP] + 8.6 (± 0.4) with a correlation 
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Figure 2.5 ATP calibration curve. Logarithm of chemiluminescent intensity (I) vs logarithm of ATP 
concentration in the range 9.54 nM - 39.1 uM. Least square analysis reveals linear behavior [log 1 = 0.81 
(± 0.06) log[ATP] + 8.6 (± 0.4)] and a correlation coefficient R2 of 0.9982 (± 0.0047) (± standard 
deviation). The ATP standards (100 u.L) in PSS at the concentrations indicated in the figure were mixed 
with 100 uL of luciferin-luciferase assay solution (Section 2.2.3). Chemiluminescence intensities were 
recorded at 22 °C. Each data point represents the average of 15 independent measurements. 
2.3.1.1 Interferences 
The effect of nitroglycerin on the luciferin-luciferase ATP assay was investigated 
to determine if the drug altered the luminescent signal. ATP standard solutions were 
divided into two aliquots. one was mixed with assay solution and the second with assay 
solution plus 33.3 |iM nitroglycerin. The results shown in Figure 2.6 confirm that the 
ATP standards with or without nitroglycerin fall on the same line. Thus, nitroglycerin 
does not interfere with the assay and the difference in the slopes of the calibration curve 
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Figure 2.6 ATP calibration curve in the presence and absence of nitroglycerin. Logarithm of 
chemiluminescence intensity (I) vs logarithm of ATP concentration in the range 38.2 nM - 39.1 U.M least 
square analysis reveals linear behavior both in the presence (*: y = 0.7793x + 8.388) and absence (D: y = 
0.7553x + 8.2923) of 3.33 mfvl of nitroglycerin, with corresponding correlation co-efficients R2 of 0.9978 
and 0.9975. See Figure 2.5 for experimental conditions. 
2.3.2 Effect of Hct on chemiluminescence intensity 
To determine a suitable RBC concentration for the extracellular ATP assay, the 
profile of light intensities at different Hct values was tested following mixing with the 
assay solution. Spence et al. used 7% Hct (8, 37, 105) in their flow-through system. For 
our experiments, RBC concentrations varying from 5-24% Hct were mixed with 
luciferin-luciferase assay solution to study the ATP signal. The results shown in Figure 
2.7 indicate no relationship between the measured ATP concentration and Hct, 
suggesting saturation of the signal. The standard curves in Figures 2.5 and 2.6 reveal that 
the light intensity is directly proportional to the ATP concentration up to -40 U.M. The 
extracellular ATP concentrations in Figure 2.7 are outside this range. 
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Figure 2.7 Measured extracellular ATP vs Hct. The ATP concentration was determined from the light 
intensities using the calibration curve in Figure 2.5. RBCs at 5-24% Hct (100 U.L) were mixed with 100 (JJL 
of assay solution. The lack of correlation between ATP concentration and Hct suggests signal saturation. 
Thus, lower Hcts were assessed. The light emitted from solutions varying from 0-
3.5% Hct was measured and the results (Figure 2.8) indicate a linear correlation up to 1% 
Hct. Linearity is lost above 1% Hct. indicating that the signal saturates at relatively low 
ATP concentration using a plate reader. A value of 1% Hct was chosen for all subsequent 
measurements of extracellular ATP. since it yields a high signal response within the 













0.00 0.05 0.10 0.25 0.50 1.00 2.50 3.50 
Hct (%) 
Figure 2.8 Measured extracellular ATP at low Hct. The ATP concentration was determined from the 
light intensities using the calibration curve in Figure 2.5. RBCs at 0-3.5% Hct (100 uL) were mixed with 
100 uL of assay solution. A linear correlation between ATP concentration and Hct is observed between 0 
and l%Hct. 
2.3.3 HPLC determination of extracellular ATP and its metabolites 
Since ATP is readily metabolized to ADP. AMP and other metabolites, the 
presence of extracellular ATP and its metabolites was investigated by HPLC using 
methodology and chromatograms published by Coolen et al. for whole blood (104). A 
HPLC-UV (254 nm) calibration curve for ATP concentrations in the range examined by 
chemiluminescence (9.54 nM - 39.1 U.M), was prepared by plotting the area under the 
ATP peak observed at 4 min. A linear correlation was observed (Figure 2.9) with a 
correlation co-efficient R2 of 0.9944. 
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Figure 2.9 HPLC-UV (254 nm) calibration curve for ATP. Plot of peak area at 254 nm vs ATP 
concentration. Linear correlation with the equation y = 0.977x + 7.388 and correlation coefficient R2 = 
0.994. The y-axis corresponds to the area under the ATP peak at 4 min in the HPLC/UV chromatogram. 
ATP standards (9.54 nM - 39.1 uM) prepared in 50 mM phosphate buffer (pH 6.0) were injected and 
eluted from a 100x4.6mm C,8 column as described in Section 2.2.4. 
Chromatographic analysis of the extracellular medium revealed the ribonucleotide 
profile. The detected levels of adenosine monophosphate (AMP) were ~18-fold higher 
than those of ATP (-0.3 U.M) (Figure 2.10). Coolen et al. reported that the ribonucleotide 
profile depends on the anticoagulant used in the blood-collection tubes. Overall, lower 
levels of ATP are detected when blood is collected in Li-heparin compared with EDTA-
coated tubes. EDTA chelates Ca + which inactivates ATP-degrading enzymes (106). 
Therefore, there is a slower rate of ribonucleotide degradation in EDTA vs Li-heparin-
coated tubes (104, 106). 
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Figure 2.10 HPLC-UV (254 nm) analysis of extracellular RBC-derived ribonacleotides. (A) 
Chromatographic profile of RBC-derived ribonucleotides from blood drawn in heparinized tubes. (B) AMP 
levels (~6 (iM) are ~18-times higher than ATP levels (0.3 uM). RBCs prepared as described in Section 
2.2.2, were resuspended at 10% Hct in sucrose buffer at 4 °C for 2 h, 200 |iL of supernatant was 
concentrated to 50 U.L using a 10-kDa cut-off ultrafiltration membrane and a 1:4 dilution of the ultrafiltrate 
in 50 mM phosphate buffer (pH 6.0) was injected and eluted from a 100*4.6mm C|8 column as described 
in Section 2.2.4. Peaks at 3.5 and 3.7 min in (A) were not identified. 
The ribonucleotide profiles examined here from blood collected in Li-heparin and 
EDTA-coated tubes showed no marked difference in AMP/ATP ratio (Figure 2.11). 
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However, Coolen et al. also reported that ATP is largely converted to AMP in RBCs 
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Figure 2.11 HPLC-UV (254 nm) analysis of extracellular RBC-derived ribonucleotides from blood 
collected in Li-Heparin and EDTA-coated tubes. RBCs were treated as described in the legend of Figure 
2.10. The extracellular medium was examined 2 h after blood collection. This experiment was carried out 
only once. 
ATP is converted to AMP via different mechanisms. Under physiological 
conditions, ATP is directly converted to AMP via ecto-nucleotide pyrophosphatase/ 
phosphodiesterase (E-NPP) and, to a lesser extent, ecto-nucleoside triphosphate 
diphosphohydrolase-1 (E-NTPDase-1) (Figure 2.12). These are ubiquitous enzymes 
found in RBCs (107, 108) and a variety of tissues in mammals, including brain (109), 




A chemiluminescent assay to measure extracellular ATP in RBC suspensions at 
low Hct was developed. Suitable RBC and luciferin-luciferase concentrations were 
established to obtain high instrument response without signal saturation. This method 
could be extended to the analysis of pharmacologically treated RBCs in order to 
determine the effects of drugs on the release of ATP or other chemical signals arising 
from these cells. 
The HPLC-UV method presented revealed that AMP is the major extracellular 
ribonucleotide detected in RBC suspensions. It is hypothesized that the ATP released 
from hypoxic RBCs is rapidly metabolized to AMP by the enzymes shown in Figure 
2.12. Hence the release of AMP from RBCs should also be evaluated. The HPLC 
approach used here for the detection of ribonucleotides could be employed to study the 
role of nucleases in the regulation of ATP levels in blood and plasma. 
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3. Effects of nitroglycerin and nitrite on ATP release from human 
red blood cells 
3.1 Introduction 
Recent research has considerably modified our understanding of the relative 
importance of central versus local regulation of blood flow. There is now compelling 
evidence that the endothelium plays an active role in the regulation of the 
microcirculation (9, 29, 34. 112). Importantly, in endothelial-mediated vasodilation is the 
formation and release of NO, which is also known as EDRF (endothelium-derived 
relaxing factor) (113, 114). Stimulation with adenosine triphosphate (ATP) released from 
red blood cells (RBCs) (115), and other regulators (116) results in increased NO 
production and release from endothelial cells. NO uptake by adjacent smooth muscle 
cells leads to relaxation via the well-documented NO/cGMP pathway (117, 118), and the 
outcome is enhanced blood flow. 
Increased muscle metabolism, as occurs during exercise, triggers "ascending 
vasodilation" to augment blood flow to the active muscles (115). The capillaries, 
arterioles, and venules contribute to the enhanced blood flow in a coordinated manner but 
mechanisms by which the vasodilatory signal is propagated remains to be fully elucidated 
(3, 119). O2 gradients are the principal regulators of blood flow in the microvasculature 
(3-6). Decreases in blood O2 content result in increases in blood flow and vice versa 
(120). Thus, signal transduction pathways that induce vasodilation must exist between 
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tissues and the microvasculature. As stated recently by Singel and Stamler, "...a general 
principle of physiology holds that cells precisely regulate their primary function. For 
RBCs this primary function is the delivery of O2 to tissues" (120). Since O2 delivery is 
determined primarily by blood flow rather than by O2 saturation of hemoglobin (120, 
121), RBCs should be capable of triggering blood vessel dilation to regulate blood flow. 
The current consensus view is that this involves O2" and hemoglobin-linked NO 
production and release from RBCs (21, 122, 123). While mechanisms of NO production 
inside RBCs, such as the nitrite reductase activity of deoxyhemoglobin, have been well 
documented (20, 124, 125), there are conflicting theories as to the mechanism by which 
NO or an NO-derived vasodilator is released into the circulation (11, 123, 126, 127). In 
fact, to the best of our knowledge, the efflux of NO (or any NOx) from RBCs has not 
been demonstrated in vivo or in vitro whereas NO (or EDRF) release from the 
endothelium has been convincingly demonstrated by a number of groups (112, 113, 128-
130). 
In contrast to the lack of evidence for NO release, ATP export from RBCs as a 
response to stimuli including hypoxia, structural deformation, and chemical agonists has 
been widely documented (7, 8). Moreover, the generation of NO in the endothelium is 
stimulated by RBC-derived ATP (9, 43). The vasodilatory power of NO is exploited 
pharmacologically in the treatment of cardiovascular diseases, such as angina pectoris, 
since nitro drugs including nitroglycerin are believed to act via the production of NO in 
vivo (50). The mechanism of nitroglycerin bioactivation has been a matter of much 
debate (54, 58, 61, 63, 70, 73, 131) but the current view is that this anti-anginal and anti-
ischemic prodrug is reduced by thiols to release NO2" (77. 132), which is considered to be 
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an important store of NO vasoactivity in blood and tissues (133) Since nitroglycerin is 
rapidly taken up by RBCs in whole blood (52, 134), we speculated as to its effects on 
ATP release from these cells. In this work, we report our findings following the exposure 
of freshly isolated human RBCs to pharmacological concentrations of nitroglycerin and 
physiological NO2" concentrations. Our results reveal that nitroglycerin-derived NO2" 
promotes ATP release from RBCs thereby contributing to the therapeutic efficacy of the 
drug. Furthermore, since NO is generated by the nitrite reductase activity of 
deoxyhemoglobin (20, 125), 
N02" + 2deoxyHb + 2H+ -> HbFe"NO + metHb + H 2 0 (3.1) 
we propose that enhanced NO production in RBCs leads to changes that stimulates ATP 
export, and that the nucleotide is a mediator of NO vasoactivity. Our findings constitute 
the first report of vasodilator release from RBCs following stimulation by an endogenous 
NO donor (NO2") as well as the seminal observation that nitroglycerin modulates levels 
of an endogenous vasodilator (ATP). The far-reaching implications of ATP involvement 
in the transduction of the NO signal between RBCs and the endothelium are discussed. 
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3.2 Materials and methods 
3.2.1 Materials 
Blood collections were done in 4-mL Vacutainer® heparinized tubes (BD, 
Franklin Lakes, NJ). KC1, MgCb, Fisherbrand 3.0 mL disposable cuvets and ethanol 
were purchased from Fisher Scientific (Pittsburgh, PA). CaCb and MgSC>4 were 
purchased from ACP Chemicals (Montreal, QC). NaCl, 
tris(hydroxymethyl)aminomethane and dextrose were purchased from Bioshop 
(Burlington, ON). Sucrose was purchased from Anachemia (Lachine, QC). Bovine serum 
albumin, ATP, firefly lantern extract, HEPES, EGTA, NaNOj and propylene glycol were 
purchased from Sigma-Aldrich (St. Louis, MO). Distilled water was purified in a Milli-Q 
Simplicity 185, Millipore (Billerica, MA). White 96-well plates were purchased from 
Corning (Corning, NY). Nitrogen gas was purchased from Praxair (Danbury, CT). 
Nitroglycerin as Nitroject® was purchased from Omega Ltd. (Montreal, QC). 
Physiological salt solution (PSS) at pH 7.4 was prepared from (in mM): 4.7 KG, 2 
CaCb, 1.2 MgSO. 140.5 NaCl, 21 tris(hydroxymethyl)aminomethane, 11 dextrose with 
0.5% w/v bovine serum albumin); and sucrose buffer at pH 7.4 from (in mM): 321 
sucrose, 32 HEPES, 3 EGTA, 6 MgCl2). The buffer pHs were adjusted to 7.4 by adding 
aqueous solution of sodium hydroxide (NaOH) or hydrochloric acid (HCI). 
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3.2.2 Preparation of red blood cells 
All procedures involving the collection of human blood samples were in 
accordance with the Concordia University Ethics Guidelines. After their informed written 
consent was obtained, blood was collected from healthy female volunteers (aged between 
20-35 years) by venipuncture into the heparinized tubes. Within 2-4 h of collection, the 
blood was centrifuged at 5000 rpm at 4 °C for 10 min. The plasma was collected by 
aspiration and stored at -80 °C. The buffy coat was also collected by aspiration and 
discarded. Packed RBCs were resuspended and washed three times in PSS. 
3.2.3 Measurement of ATP 
From a stock solution of 2.5 mM ATP in PSS. ATP standards ranging from 10 
nM to 40 |j,M ATP were prepared in PSS. The luciferin-luciferase assay solution used to 
measure ATP by chemiluminescence was prepared by dissolving 13.3 ing of crushed 
firefly extract in 10.0 mL of Milli-Q water. Chemiluminescence proportional to the ATP 
in the sample was measured using a Wallac Victor 1420 multilabel plate reader 
(PerkinElmer, Waltham, MA). Background emission of 100 uL of the luciferin-luciferase 
assay solution in a white 96-welI plate was recorded, and immediately after 100 \iL of 
each ATP standard was added and the chemiluminescence intensity was measured. 
Following background correction, double log plots of intensity I vs [ATP] yielded a 
linear standard curve over 10 nM- 40 \iM. To measure sample ATP levels. 100 uL of 
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RBCs at different Hct values were added to 100 u.L of the blanked luciferin-luciferase 
assay solution, the light intensity was recorded, and ATP concentrations were determined 
using the ATP standard curve. To prepare anoxic RBCs, a 1.5-mL solution of cells at 1% 
Hct was sealed in a 5-mL vial with a crimpable aluminum seal. Nitrogen gas was bubbled 
over the surface of the solution at 5 psi for 15 min, and the ATP concentration of a 100 
u.L aliquot of the hypoxic RBCs was measured as described above. 
3.2.4 Exposure of RBCs to nitroglycerin 
From a commercial stock solution of 5 mg/mL (22 mM) nitroglycerin, 100 |LLL 
dilutions (0.05 - 2.0 mM) were prepared in 5% w/v aqueous dextrose (278 mM D-
glucose). Packed RBCs (20 u\L) were mixed with 20 [J.L of each nitroglycerin dilution 
and 260 flL of sucrose buffer. RBCs at 7% Hct where incubated at 37 °C for 1 h in a 
water bath without shaking, centrifuged at 5000 rpm at room temperature for 45 s, the 
supernatants were removed, RBCs at 1% Hct were suspended in PSS, 100 |iL were 
mixed with 100 |xL of luciferin-luciferase assay solution and concentrations of 
extracellular ATP were measured as described in Section 3.2.3. A control sample 
prepared with 20 [J.L drug vehicle only (30% v/v ethanol, 30% v/v propylene glycol and 
40% v/v water) was treated and analyzed in the same manner. 
To probe the effects of preincubation time on ATP release, packed RBCs were 
diluted to 2% Hct in sucrose buffer containing 10 |iM nitroglycerin at 37 °C. Aliquots of 
1 mL were removed from the mixture over 0-60 min, immediately centrifuged at 5,000 
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rpm at room temperature for 45 s, the supernatants were removed, solutions at 1% Hct 
were prepared in PSS, and concentrations of extracellular ATP were measured as 
described above. 
3.2.5 Exposure of RBCs to nitrite 
NaN02 stock solutions (0.5, 2.5, 5.0, 10.0, 25.0 and 50.0 pJVl) were prepared in 
5% w/v aqueous dextrose (278 raM D-glucose). Packed RBCs (20 uL) were mixed with 
260 (iL of sucrose buffer and with 20 |lL of each stock NaNC>2 solutions, leading to the 
following nitrite concentrations (nM) during the incubation: 33, 167, 333, 667, 1667, 
3333. The samples were treated and analyzed as described in Section 3.2.3. The effects of 
incubation time on extracellular ATP were also examined by incubating 200 jiL of 
packed RBCs with 200 uX of NaN02 (final concentration of 2% Hct and 100 nM 
NaNCh) in 9.6 mL of sucrose buffer at 37 °C. Aliquots of 1 mL were removed over 0-60 
min, centrifuged, and analyzed for ATP release as described in Section 3.2.3. 
3.2.6 Statistical methods 
Statistical significance between experimental runs was determined with Student's 




3.3.1 Hypoxia-induced release of ATP 
To validate our method, the well-documented increases in ATP release from 
RBCs in response to hypoxia (37, 135) was first examined. Prior exposure of RBCs to N2 
for 15 min increased the extracellular ATP concentration by 1.6-fold compared to RBCs 
maintained in vials exposed to air (Figure 3.1). This increase in ATP under anoxic 
conditions is less than that observed by Faris and coworkers (37), but they measured 
prompt changes in ATP within 15 min of exposure to N2. Figure 3.2A shows the 
variation in ATP release from RBCs from six healthy, age-matched, volunteers. An 
average ATP increase of 13±4 nM was observed, where the error reflects both biological 
and assay variability. Interestingly, volunteers #3-5, whose RBCs released higher 
concentrations of ATP, were also actively involved in exercise training. Measurements 
on the blood from volunteer #1 at 4 h and 26 h after collection revealed that the amount 
of ATP exported decreases as cells age, which may reflect a decrease in total RBC ATP 
with time following blood collection (136). 
The average extracellular ATP reported in the present work (26±4 nM) can be 
compared with the data reported by Meyer et al. (105), who measured extracellular ATP 
from cells at 7% Hct. When normalized to 1% Hct, the equivalent of 37±8 nM 
extracellular ATP was reported (n=7), which is comparable to our average value (n = 6). 
This agreement is noteworthy given that our experimental approaches are different: 
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Meyer et al. (105) used a flow-through set up containing 7% Hct whereas our 
measurements were made following mixing 100 U.L of cells at 1% Hct with 100 pL of 
luciferin-luciferase assay solution in a static plate-reader as outlined in Section 3.2.2. 
Furthermore, the breakdown of released ATP by ATPases renders the assay time 
sensitive (Section 2.4.4). We, like previous workers in the field (37, 103), used heparin-
containing tubes. Although less ATP breakdown should occur in EDTA tubes due to Ca2+ 
chelation, which inactivates ATPases (104), no difference was noted here using the 




























Figure 3.1 Hyposia-induced ATP release from fresh human RBCs. Cells from the venous blood of four 
healthy volunteers were treated as described in Section 3.2.2. The extracellular ATP from the RBCs at 1% 
Hct in PSS from cells stored in a vial at 22 °C under air (control, filled bar) and under nitrogen for 15 min 
(N2, open bar). The ATP concentration was determined in triplicate by a luciferin-luciferase 
chemiluminescence assay at 2 h after blood collection. The error bars represent the standard error of the 




- 40 J B ! 
£ 3 0 J y 1 | 
< i : 
S 20 J ! 
.2 ' 
E 10 J | 
0 I 1 ! 
This work Reported 
Figure 3.2 Hypoxia-induced increase in extracellular ATP. (A) ATP in PSS containing fresh human 
RBCs from the venous blood of six volunteers was measured as described in the legend of Figure 3.1 at 4 h 
(filled bar) or 26 h (open bar) following blood collection. (B) Comparison of average values for ATP 
release from (A) and those reported from cells in PSS at room temperature by Meyer et al. (105). 
3.3.2 Effects of preincubation with nitroglycerin at various concentrations on 
extracellular ATP 
Fresh RBCs from venous blood were first incubated with varying concentrations 
of nitroglycerin. As Figure 3.3A shows. 60-min preincubation of cells with nitroglycerin 
inhibits ATP release in a dose-dependent manner. The extracellular ATP concentration is 
reduced by 35% and 42% in the presence of 33 M.M and 133 uM nitroglycerin, 
respectively. Since nitroglycerin is metabolized to nitrite, RBCs were exposed to 3.3-133 
uM NaNC»2 but a foul odor was detected and immediate and dramatic darkening of the 
cells was observed. The latter is likely due to extensive formation of methemoglobin, 
which is dark brown in color (137), via two pathways: Reaction 3.1 and the scavenging 
of the NO produced by oxyhemoglobin to generate nitrate (NO3) as well as 











the drug. Considering that physiological NO2" levels are in the nanomolar to low 
micromolar range (138), we next investigated the effects preincubation with of 33-3333 
nM NaNC>2 on ATP release from RBCs. As Figure 3.3B reveals, this lower level of NO2" 
results in extracellular ATP levels similar to those seen at the higher nitroglycerin 
concentrations; for example, 60 min after exposure to 167 nM and 667 nM NO2", the 
extracellular ATP concentration dropped by 18% and 36%, respectively. We attribute the 
comparable efficacy of nanomolar NO2" and micromolar nitroglycerin as inhibitors of 
ATP release to the relatively slow metabolism of the prodrug. Assuming that NO2" (or 
NO derived from NO2) is the effective inhibitor of ATP release, then only -0.5% of 
nitroglycerin is metabolized to NO2" within the RBC over 60 min since a 80-fold lower 
NO2" concentration produces a similar effect as nitroglycerin (e.g., 133 (iM nitroglycerin 
vs. 1667 nM NO2" attenuates ATP levels by -50% whereas 6.7 |lM nitroglycerin vs. 167 
nM NO2" cause -20% attenuation, Figure 3.3). The effects of both nitroglycerin and NO2" 
also appear to be saturateable (Figure 3.3), which combined with their similar attention of 
ATP release, suggest that NO2" (or NO) may actually contribute to "nitrate tolerance" as 
discussed below. Extracellular ATP was measured here immediately following transfer of 
cells from the preincubates with NO2" or nitroglycerin (Sections 3.2.3 and 3.2.4). 
However, ATP is not expected to accumulate with time in the RBC suspension, due to 
the action of RBC ATPases (104, 106). 
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Figure 3.3 Variation in extracellular ATP following 60 min preincubation of intact human RBCs at 
7% Hct with nitroglycerin and N02". Effects of (A) nitroglycerin and (B) N02" concentrations on the 
extracellular ATP levels displayed as normalized averages for cells from five (A) and three (b) volunteers 
where the control values (no stimulant) were normalized to 1.0 for each volunteer. The error bars denote 
the standard error of the mean (± s.e.m.) and represent assay variability. Approximately 2 h after blood 
collection, control, vehicle, and sample cells were diluted to 7% Hct in sucrose buffer only (control), in 
sucrose buffer with 7% v/v drug vehicle (30% v/v ethanol, 30% v/v propylene glycol and 40% v/v water), 
and in sucrose buffer with stimulant, respectively, and preincubated at 37 °C for 60 min. Following RBCs 
resuspension at 1% Hct in PSS, and addition of an equal volume of assay solution, the extracellular ATP 
concentrations were determined by a luciferin-luciferase chemiluminescence assay (see Section 3.2.2). *: P 
values, determined using Student's /-test, are given for P < 0.05 
33.3 Extracellular ATP vs nitroglycerin and nitrite preincubation time 
Since both nitroglycerin (54, 139) and nitrite (122, 134) are known to induce 
vasodilation within minutes, we next examined release at different times after cells were 
preincubated with a pharmacologically relevant concentration of the drug. As Figure 
3.4A shows, a 150% increase in ATP concentration is observed after 30 s preincubation 
with 10 ]\M nitroglycerin. The ATP level stabilized to the control value within 15 min 
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preincubation. On exposure to 100 nM NaNC>2 (Figure 3.4B) an immediate 100% 
increase in extracellular ATP concentration was followed by a profile similar to that 
observed for nitroglycerin (Figure 3.4B). The 30-s or so slower nitroglycerin-induced 
spike in ATP efflux from RBCs is attributed to the time required for bioactivation of the 
prodrug by these cells to yield NO2". Bioactivation is obviously not necessary in the case 
ofNaN02. 
^ 6® 0 0.5 1 2 5 15 30 45 60 Control 0 0.5 1 2 5 15 30 45 60 
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Figure 3.4 Variation in extracellular ATP following 0-60 min preincubation of intact human RBCs at 
2 % Hct with nitroglycerin and N02". Preincubation at 37 °C in sucrose buffer containing (A) 10 (rM 
nitroglycerin and (B) 100 nM NaN02. Results are displayed as averages (means ± s.e.m.) for cells from 
five volunteers where the control values (no stimulant) were normalized to 1.0 for each volunteer. See 
legend of Figure 3.2 for experimental details. *: P values, determined using Student's /-test, are given for P 
<0.05. 
We also investigated whether a spike in ATP release would be observed each time 
a bolus of nitroglycerin or NaNC>2 was added to the cells. Preincubation a second time 
with 10 u.M nitroglycerin of cell previously preincubated for 60 min with nitroglycerin 
resulted in negligible change in the ATP concentration (data not shown). Likewise, 
preincubation with 100 nM NaNC>2 did not alter the ATP level. The same results were 
observed for the cells in Figure 3.4B. which were first preincubated with 100 nM NaNCb 
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rinsed in PSS and then preincubated with NaNC>2 or nitroglycerin after 60 min. Since the 
extracellular ATP levels did not change, the cells appear to have lost their responsiveness 
to the NO donors, which may contribute to the nitrate tolerance observed in patients on 
nitrates as discussed further below. 
3.4 Discussion 
As transducers of tissue ischemia, RBCs play a pivotal role in triggering increased 
blood flow in the microcirculation (6, 119, 120). In this work, we report that 
preincubation of freshly isolated human RBCs with pharmacological concentrations of 
nitroglycerin results in an initial spike in ATP efflux. Within 15 min of preincubation, the 
amount of extracellular ATP detected from nitroglycerin-exposed cells was the same as 
that from control cells but dropped to 34% below the control after 30 min (Figure 3.4A). 
The effects of physiological concentrations of NO2" mirror those of nitroglycerin but the 
ATP spike was within the mixing time (Figure 3.4B). Since NO2" is a metabolite of 
nitroglycerin (3, 58, 73), the combined results in Figure 3.4 indicate that nitroglycerin-
derived NO2" stimulates ATP release from human RBCs. We propose that this key 
finding is a contributory factor in the therapeutic effects of nitroglycerin. The prodrug is 
metabolized by RBCs to provide a controlled release of NO2" which stimulates ATP 
export. This constitutes the first report of vasodilator release following RBC stimulation 
by an endogenous (NO2) or a pharmacological NO donor (nitroglycerin). Since NO2" is 
reduced to NO in RBCs (Reaction 3.1) (122), we further propose that RBC-derived ATP 
is a regulator of NO-mediated vasoactivity in the circulation. 
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Figure 3.5 Proposed chemical physiology of blood flow regulation by ATP and NO/N02" pathways 
RBC (cell-A) stimulated by nitroglycerin or its vasoactive metabolite, N02", causes a rapid increase in ATP 
efflux. Since N02~ is converted to NO within RBCs, the latter may be the direct effector of enhanced ATP 
release. In an intact blood vessel, ATP will bind to purinergic receptors on the endothelium and stimulate 
endothelial nitric oxide synthase (eNOS) (140) thereby increasing levels of TMO/EDRF that exert relaxation 
of smooth muscle cells, causing vasodilation. NO also diffuses to the vascular lumen where it is converted 
to N02" by the action of ceruloplasmin (18), and taken up by downstream RBCs (cell-B), which further 
increases their ATP production. Thus, the original RBC-derived N027NO signal is amplified both by the 
action of ATP on the endothelium and by the NO/EDRF released into the lumen, which gives rise to a 
positive feedforward mechanism and propagated vasodilation. The signal is shut-off by attenuating ATP 
release from RBCs after a certain period of exposure to elevated N02", suggesting that N027NO can also 
inhibit ATP release. 
Our seminal findings and their implications in vasodilation are summarized in Figure 
3.5. NO/EDRF released from the endothelium not only diffuses to the vascular smooth 
muscle cells, but is also released into the vascular lumen where it is converted to NO2", 
and plasma NO2" levels are considered an index of eNOS activity (141). RBCs take up 
NO2". which may directly, or following its reduction to NO (Reaction 3.1). give rise to a 
NO, 
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spike in ATP release by an as yet unknown signaling pathway that may involve the 
heterotrimeric G protein, Gj (142). Since RBC-derived ATP is an agonist for NO/EDRF 
production by the endothelium (143), RBC NO2" uptake from the lumen and RBC ATP 
release into the lumen will occur in intact blood vessels. Since RBCs are in transit, 
downstream cells (B in Figure 3.5) will also be exposed to higher NO2" levels, which will 
serve to propagate a vasodilatory signal. 
The model in Figure 3.5 is compatible with the chemical stability of the signaling 
molecules involved. ATP and NO2" are relatively stable species that can survive in the 
vascular lumen whereas NO reacts readily with O2 and O2" (144, 145). Thus, while NO 
may endure direct transfer from the endothelium to the adjacent vascular smooth muscle, 
is it less likely to survive export from RBCs and indirect delivery to smooth muscle cells. 
Our model not only would ensure that the unstable NO/EDRF message reaches the 
smooth muscle, it also provides mechanisms for propagated vasodilation: RBC-derived 
ATP amplifies the vasodilatory signal from the endothelium, and reuptake from the 
lumen by downstream RBCs of the NO/EDRF-derived NO2" (Figure 3.5) would result in 
a positive forward mechanism. 
However, despite its efficiency as an anti-anginal, anti-ischemic prodrug, the 
vasodilatory response to nitroglycerin diminishes with continuous use, giving rise to 
nitrate tolerance (146). Many hypotheses have been developed to explain the mechanism 
by which tolerance is developed, including decreased activation of the NO/cGMP 
signaling pathway, reduced bioconversion of nitrates to NO, and enhanced production of 
superoxide anions that destroy NO (50). Here we have shown that there is attenuation in 
the extracellular ATP released from RBCs preincubated with nitroglycerin orN02_ for 30 
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min or less (Figure 3.5). Also the cells do not respond to a second preincubation with the 
NO donor. Both NO-donors activate an initial rapid spike in ATP efflux followed by a 
drop-off (Figure 3.4) and loss of responsiveness. We hypothesize that ATP release is 
attenuated following exposure of RBCs to relatively high levels of nitroglycerin or NO2" 
via a negative feedback mechanism, which would be essential to prevent over dilation of 
blood vessels. This mechanism is also likely to contribute to nitrate tolerance. 
Since NO2" is converted within RBCs to NO via Reaction 3.1. the data in Figure 3.4 
are also consistent with the report that decreased ATP was observed in the medium 20 
min after incubation of RBCs with 0.1 rnM spermine NONOate, which spontaneously 
releases NO (147). ATP levels following shorter exposure times to the NO donor were 
not reported (147), but we speculate that NO may be the causative agent in ATP release 
and that attenuation of ATP efflux may be due to "NO tolerance". Alternatively, NO is 
oxidized to NO2*, and overstimulation with NO2" leads to "NO-tolerance". Regardless of 
the NOx involved, the proposed NOx-induced vasodilation mechanism shown in Figure 
3.5 would eventually lead to hypotension. Thus, it is clearly essential for survival that a 
negative feedback mechanism exist. We suggest that NOx contributes to this negative 
feedback on stimulation with high NOx levels, and that NOx tolerance may be a more 
appropriate description for nitrate tolerance. 
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4o Effects of nitroglycerin on gIyceraldehyde-3-
dehydrogenase activity 
4.1 Introduction 
The role of GAPDH in the bioactivation of nitroglycerin has been introduced 
previously in Section 1.2.2.6. GAPDH is a tetramer of molecular weight 144,000 Da that 
plays a key role in glycolysis by catalyzing the NAD-mediated oxidative phosphorylation 
of glyceraldehydes-3-phsphate to D-l,3-byphosphoglycerate (Figure 4.1) (148). The 
enzyme consists of four identical noncovalently bonded polypeptide chains (36,000 Da) 
each accommodating one molecule of NAD+ as coenzyme (149). The enzyme is used for 
the determination of D-glyceraldehyde-3-phosphate, NAD+, inorganic phosphate (Pi), 
ATP, 1,3-byphosphoglycerate and phosphoglycerate kinase activity (150). 
OH OH 
^ R ^ \ ^ \ ^ — ^ - ^ •»• ^ R ^ ^ ^ ^ - ^ FT 
HO \ ) H NAD+ + Pi NADH + H* HO^ \>H H<J WOH 
glyceraldehyde-3-phosphate 1,3-biphosphoglycerate 
Figure 4.1 GlyceraIdehyde-3-phosphate conversion to 1,3-biphosphoglycerate. GAPDH's catalytic role 
in this reaction is NAD+ dependent. The absorbance change at 340 nm on NAD+ reduction to NADH was 
used in this project for the spectrophotometric determination of GAPDH activity. 
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In vitro studies in our lab have shown that nitroglycerin, like glyceraldehyde-3-
phosphate (G3P), acts as a substrate for the GAPDH (M. Antonic et al., unpublished 
results). GAPDH catalyzes the reduction of nitroglycerin to 1.2- and 1,3-glycerol 
dinitrate (GDN) and nitrite (Reaction 4.1). The nitrite produced could be then further 
reduced in RBCs by deoxyHb to NO (Reaction 3.1). This mechanism represents a 
possible pathway for nitroglycerin bioactivation in the blood stream, resulting in the 
desired vasodilatory response induced by nitric oxide. 
GAPDH 
Nitroglycerin • 1,2-GDN + 1,3-GDN + NOz" (4.1) 
Our previous research also demonstrated that nitroglycerin inhibits GAPDH 
glycolytic activity. This inhibition would not only affect the bioconversion of 
nitroglycerin to NO but, since GAPDH plays an important catalytic role in glycolysis, the 
production of ATP in the RBC would be attenuated. The importance of ATP in 
vasodilation was discussed in Chapter 3. 
Preliminary research in our laboratory with rat RBCs and purified GAPDH from 
rabbit muscle (R. Kennedy, unpublished data) set the basic parameters for the assessment 
of GAPDH activity in lysed human RBCs. As shown in Figure 4.2, the glycolytic activity 
of GAPDH from lysed rat RBCs follows a similar profile to purified GAPDH from rabbit 
muscle and can be measured using the same experimental protocol. 
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Figure 4.2 Glycolytic activities of purified GAPDH (from rabbit muscle) and GAPDH from RBC 
lysate. Glycolytic activity of 1 uM GAPDH purified from rabbit muscle and 233 uL of rat RBCs lysate was 
measured. Assay with purified GAPDH was performed in sodium pyrophosphate buffer adjusted to pH 8.5 
at 22 °C. Assay for GAPDH in cell lysate was performed in sucrose buffer adjusted to pH 7.4 at room 
temperature. In both cases 0.4 M potassium arsenate was used as substrate. Reduction of NAD+ to NADH 
was monitored at 340 nm for 4 min using a Beckman DU-650 spectrometer. Absorbance values are 
adjusted so that A0 = 0 at t = 0 s. Adapted from R. Kennedy, unpublished data. 
The concentration-dependent effect of nitroglycerin on GAPDH's glycolytic activity 
was also assessed in previous work. Experimental observations showed that the activity 
of GAPDH from lysed rat RBCs diminished with increasing concentration of 
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Figure 4.3 Effect of nitroglycerin on the glycolytic activity of GAPDH from rat RBC lysate. Lysed rat 
RBCs were incubated for 1 h at 37 °C with the nitroglycerin concentrations indicated in the presence of 
0.0) M glyceraldehyde-3-phosphate, 0.01 M NAD+ and 0.4 M potassium arsenate in sucrose buffer at pH 
7.4. Reduction of NAD+ to NADH was monitored at 340 nm for 4 min using a Beckman DU-650 
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Figure 4.4 Bar graph of the effect of nitroglycerin on the glycolytic activity of GAPDH from rat 
RBCs. Lysed rat RBCs were incubated for 1 h at 37 °C with the nitroglycerin concentrations indicated in 
the presence of 0.01 M glyceraldehyde-3-phosphate. 0.01 M NAD+ and 0.4 M potassium arsenate in 
sucrose buffer at pH 7.4. Reduction of NAD+ to NADH was monitored at 340 nm for 4 min using a 
Beckman DU-650 spectrometer. Activities are given relative to the control (no nitroglycerin) at t = 0 s. 
Adapted from R. Kennedy, unpublished data. 
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In this chapter the focus is on describing the effects of nitroglycerin on GAPDH 
glycolytic activity in human RBCs. In order to fulfill these goals, a method based on the 
role of GAPDH in arsenate reduction (151) was adapted to measure GAPDH activity in 
intact and lysed RBCs (Figure 4.5). These spectrophotometric assays may help determine 
the role of erythrocytic GAPDH in nitrate tolerance. 
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Figure 4.5 Arsenate vs phosphate in the conversion of gIyceryI-3-phosphate by GAPDH. For this work 
potassium arsenate is used instead of inorganic phosphate (Pi) as a GAPDH substrate to inhibit the reverse 
reaction. As5+ has the same oxidation state and shares many chemical properties with inorganic phosphate 
(P- ) and can substitute for Pi in ATP production. When using arsenate as a substrate, GAPDH produces 1-
arseno-3-phosphoglycerate rather than 1,3-bisphosphoglycerate. l-arseno-3-phosphoglycerate hydrolyzes 
spontaneously, so that ATP continues to be produced. Adapted from (152). 
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4.2 Materials and methods 
4.2.1 Materials 
Distilled water purified in a Milli-Q Simplicity 185, Millipore (Billerica, MA) 
was used to prepare all aqueous solutions. D,L-glyceraldehyde-3-phosphate, p-
nicotinamide adenine dinucleotide, sodium pyrophosphate, potassium arsenate, HEPES, 
EGTA and bovine serum albumin were purchased from Sigma-Aldrich (St. Louis, MO). 
CaCl2 and MgS04were purchased from ACP Chemicals (Montreal, QC). MgCl2 and KCl 
were obtained from Fisher Scientific (Pittsburgh, PA). NaCl, 
tris(hydroxyrnethyl)aminomethane and dextrose were purchased from Bioshop 
(Burlington, ON). Sucrose and tris-HCl was purchased from Anachemia (Lachine, QC). 
Nitrogen gas was purchased from Praxair (Danbury, CT). Nitroglycerin as Nitroject® 
was purchased from Omega Ltd. (Montreal, QC) and human blood was collectied in 4-
mL Vacutainer® heparinized tubes (BD, Franklin Lakes, NJ). All spectral measurements 
were carried out using an Agilent 8453 UV-Visible diode-array spectrophotometer 
(Agilent Technologies, Santa Clara, CA). 
4.2.2 RBCs incubation with nitroglycerin 
Packed RBCs were obtained from human blood following the procedure 
described in Section 2.2.2. Next. 20 uL of intact RBCs at 7% Hct were preincubated with 
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an equal volume of nitroglycerin of varying concentration (0 - 6.7 |J.M) in 260 uL of 
sucrose buffer (pH 7.4, prepared as described in Section 2.2.1) at 37 °C in a water bath 
for 1 h. After preincubation, samples were centrifuged at 5,000xg at 4 °C for 45 s, the 
supernatant was removed and discarded, and the packed RBCs were retained for the 
GAPDH activity assay. 
4.2.3 Assay ofRBC GAPDH activity 
The packed RBCs from Section 4.2.2 were resuspended in 33 volumes of ice-cold 
sodium saline, centrifuged, and the supernatant was removed. The cells were osmotically 
lysed at 1% Hct by adding 99 volumes of ice-cold water and sonicating for 5 min. Solids 
that may interfere with spectrophotometric analysis were removed by centrifugation at 
5,000 g at 4 °C for 45 s, the supernatant was conserved and the pellet discarded. In a 1.5-
mL Fisherbrand disposable cuvette, 700 uL of sucrose buffer, 16.7 uL of 0.01 M NAD+, 
16.7 uL of 0.01 M glyceraldehyde-3-phosphate and 16.7 uL of 0.4 M potassium arsenate 
were mixed to give the final concentrations listed in Figure 4.6. This solution was 
incubated at 22 °C for 5 min and then used to blank the spectrophotometer at 340 nm. 
The assay was initiated by adding 233 uL of RBC lysate (control or incubated with 
nitroglycerin) and the absorbance increase due to the reduction of NAD+ to NADH (Ae34o 
= 6,220 IVT'cm"') was recorded every 10 s for 4 min. 
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4.3 Results 
4.3.1 Effect of nitroglycerin on glycolytic activity of GAPDH in human RBC 
Sysates 
GAPDH activity in the Iysed RBC samples was assessed by 
spectrophotometrically monitoring NADH production, which directly relates to the 
activity of the enzyme (Figure 4.1). As seen in Figure 4.1, one mol of NADH is required 
per mol of substrate turned over by GAPDH. 
The inhibitory effect of nitroglycerin on GAPDH from human RBCs was 
demonstrated using cumulative dose-response curves (Figure 4.6). As can be seen from 
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Figure 4.6 Effects of nitroglycerin on glycolytic activity of GAPDH from human RBC lysate. (A) 
Activity of RBC GAPDH over 240 s. (B) Initial rates (0-30 s). Human RBCs at 7% Hct were incubated for . 
1 h at 37 °C with 0.0 (control). 1.7, 3.3 and 6.7 |iM nitroglycerin. RBC lysates were prepared from cells at 
1% Hct in the presence of 0.01 mM gIyceraIdehyde-3-phosphate. 0.01 mM NAD+ and 0.4 mM potassium 
arsenate in sucrose buffer at pH 7.4 at 25 °C. Reduction of NAD+ to NADH was monitored at 340 nm in a 
1-cm cuvette and the initial absorbance (due to the presence of Hb in the lysate) was subtracted from each 
value. 
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Normalization of the control to 100% activity at 240 s revealed GAPDH activity 
decreases of 6.4, 10.0, and 21.1% when a lysate of RBCs at 1% Hct was preincubated 
with 1.7, 3.3, and 6.7 |lM nitroglycerin, respectively (Figure 4.7). These values are 
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Figure 4.7 Bar graph of the nitroglycerin effect on the glycolytic activity of GAPDH from human 
RBCs. Activities are given relative to the control (no nitroglycerin) at t = 0 s. The experimental details are 
given in the legend of Figure 4.6. 
4.4 Discussion 
Activity assays for nitroglycerin-treated human RBC lysates showed that the drug 
exerts a concentration-dependent inhibitory effect on GAPDH. This Confirms the 
previous finding in our group (M. Antonic et ah, unpublished results) that nitroglycerin is 
a "suicide substrate" of GAPDH in vitro. GAPDH acts as a bioactivator of nitroglycerin 
by reducing it to nitrite and glyceryl dinitrites using active-site Cysl49 and Cysl53 as 
electron donors (Section 1.2.2.6). This results in the formation of a disulfide bond 
1.7 3.3 6.7 
[nitroglycerin] (uM) 
69 
between the two cysteines, inactivating the enzyme. RBC GAPDH inactivation could 
contribute to nitrate tolerance. Chronic exposure to nitroglycerin would decrease the 
amount of active GAPDH in the cells available to activate the drug, thereby blunting the 
effects of the drug. Compounding this effect would be the reduction in RBC ATP 
production and possibly a reduction in extracellular ATP as seen in Figures 3.5 and 3.4. 
Previous research in our lab has demonstrated that the disulfide bond in GAPDH 
can be reconverted to free cysteines by tris(2-carboxyethyl)phosphine (TCEP), a disulfide 
reducing agent (Scheme 4.1), suggesting reversible inactivation of the enzyme in vivo. 
This is also consistent with the evolution of nitrate tolerance. Upon temporary withdrawal 
from nitroglycerin treatment (e.g., 12-hour "drug holiday") the pharmacological effects 
of the drug can be experienced again. Reactivation of GAPDH in vivo would be carried 
out by the action of one or more disulfide reductase systems present in cells. These 
systems would recover the enzymatic activity of GAPDH by reducing the disulfide bond 









Scheme 4.1 Proposed mechanism of nitroglycerin bioactivation by GAPDH. GAPDH catalyzes the 
transfer of N02 from nitroglycerin to Cysl49 at its active site. This transfer is accompanied by the 
formation of 1,2- and/or 1,3-glyceryl dinitrates. Neighboring Cysl53 nucleophilically attacks the thionitrate 
group forming an intramolecular disulfide bond and releasing N02". The disulfide bond is reduced to the 
original free thiol functionalities by the reducing agent TCEP (tris(2-carboxyethyl)phosphine) or another 
disulfide-reducing system. This mechanism is based on that proposed for ALDH2 in Scheme 1.1 (59). 
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The study of the vasodilator concentrations in the blood stream could help 
elucidate the localized mechanisms of blood-flow regulation and the synergism between 
these chemical messengers. In this chapter, the development of analytical methodology 
for detection and quantitation of EETs and PGI2 in human plasma is presented. 
Specifically, the stability of EETs as well as the optimization of their analysis by mass 
spectrometry are established and 6KPGF]a was confirmed as a stable biomarker for PGI2. 
5.1.1 Epoxyeicostrienoic acids (EETs) 
EETs are cytochrome P450 metabolites of arachidonic acid that mediate muscle 
vasodilation. The most abundant isoforms are 11,12-EET and 14,15-EET, and they are 
also known to be involved in many metabolic processes including cell proliferation and 
migration (153). Additionally, it has been suggested that 11,12-EET could be the 
endothelial-derived hyperpolarization factor (EDHF) (28). EETs exert strong 
vasodilatory effects in a wide variety of tissues such as brain, intestines (159), kidney 
(160), heart and coronary arteries (154, 161, 162), and blood vessels (155, 156). 
Many methods have been reported for the detection and quantitation of EETs (33, 
163, 164). However, only a few methods have been developed for blood plasma since its 
complexity as a matrix makes the quantitative analysis of EETs challenging. A sequential 
extraction method for vasodilation-related metabolites in interstitial fluid was developed 
in our lab (164). Jiang et al. showed that detection and quantitation of EETs in plasma 
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can be performed by ESI-MS/MS (155) and an adaptation of this method is presented 
here. 
5.1.2 Prostacyclin (PGI2 
PGI2 is a member of the prostaglandin family. Physiologically classified as 
hormones, these fatty acid derivates play important roles in vasodilation, coagulation and 
inflammatory processes (34). Prostaglandins are produced from arachidonic acid by 








1 Prostaglandin G2 
Figure 5.2 Metabolic pathways of prostaglandins production. Membrane phospholipids are converted 
to arachidonic acid (AA) by phospholipase A2. AA is a substrate of both isoforms COX and it is converted 
to Prostaglandin G :. Dehydroxilation of prostaglandin G : generates prostaglandin H2, the precursor of all 
functional prostaglandins (PG12. PGD:. PGE; and PGF:). Adapted from (165). 
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Numerous methodologies have been proposed for the analysis of these substances 
in complex matrixes. Gelpi et al. highlighted the applications of liquid chromatography 
with radioimmunoassay (HPLC-RIA) for analysis of eicosanoids (166). This 
methodology involves the inoculation of viable vectors with radio labeled antigens, with 
the limitations of animal breeding and handling and the special conditions in which 
radioactive substances have to be manipulated. Daret et al. propose the analysis of 
analyzed monohydroxylated fatty acids and eicosanoids by gas chromatography with a 
mass spectrometry detector (GC-MS). This methodology involves the derivatization of 
the fatty acid-like molecules to volatile methyl esters to be suitable for GC analysis (167). 
Dickinson et al. present a very fast and efficient method for the overall study of many 
arachidonic acid derivates (168). This method was adapted to our research for the 
detection and quantitation of PGI2 which posses a short half-life both in vivo and in vitro, 
ranging from 30 seconds to a few minutes (169). It is stable in basic buffers (pH > 8) but 
is rapidly hydrolyzed through a non-enzymatic mechanism to 6-keto prostaglandin Fia 
(6KPGFia) in neutral or acidic solutions (Figure 5.3). This inactive and stable end 
product can be used as a biomarker of PGI2 (170). 
HO OH 
prostaglandin l2 (PGI2) 





6-keto prostaglandin F1a (6KPGF1a) 
Figure 5.3 Hydrolysis of prostaglandin I2 to 6-keto prostaglandin F ) a . Adapted from (169). 
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5.2 Materials and methods 
5.2.1 Materials 
ll,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid (11,12-EET), 14(^),15(5)-epoxy-
(5Z,8Z,112)-eicosatrienoic acid (14,15-EET), triphenylphosphine (TPP), magnesium 
chloride and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. 
Louis, MO). 6-keto prostaglandin Fia (6KPGF]a) and deuterated 6-keto prostaglandin F] a 
(D4-6KPGFia) were purchased from Cayman Chemical (Ann Arbor, MI). Potassium 
chloride, hydrochloric acid and methanol (HPLC grade) were purchased from Fischer 
Scientific (Pittsburgh, PA). Sodium chloride and D-glucose were obtained from BioShop 
(Burlington, ON), sodium bicarbonate from Anachemia (Lachine, QC), calcium chloride 
dihydrate ACP Chemicals (Montreal, QC), chloroform (HPLC grade) from JT Baker 
(Phillipsburg, NJ). and acetonitrile (HPLC grade) from EMD Chemicals (Gibbstown, 
NJ). Distilled water was purified in a Milli-Q Simplicity 185 and Ultrafree®-0.5 
centrifugal filter Units, 10-kDa cut-off ultrafiltration membranes were purchased from 
Millipore (Billerica, MA). Bondpack C]g, 100 mg C\g cartridges were obtained from 
Agilent Technologies (Santa Clara, CA). Nitrogen gas was purchased from Praxair 
(Danbury, CT). 
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5.2.2 Preparation of EET standards 
Solutions of 0.5 uM EETs were prepared in four different solvents (100% ACN, 
ACN/H20 (1:1), 100% MeOH and 100% H20) under indirect light and with minimum 
exposure to air. These stock solutions were maintained at -20 °C at all times during 
manipulation and stored at -80 °C immediately after use. Transfers were performed in 
glass gas-tight syringes previously cleaned with ACN and HPLC-grade methanol, and air 
dried. Dilutions containing 0.25, 0.12. and 0.06 U.M EET were prepared in each solvent 
and aliquoted into 3 batches. The first batch was analyzed on the day of sample 
preparation. The second and third batches were stored in the dark at -80 °C, and analyzed 
24 h and 6 days later. 
5.2.3 Preparation of plasma simulator 
Tyrode's buffer solution (pH 7.4) was prepared as described in (171). Briefly, an 
aqueous solution containing 0.13 M NaCl, 5.5 mM glucose, 11 mM NaHCOs, 2.6 mM 
KC1, 0.5 mM NaH2P04, 2.2 mM MgCl2, and 1.8 mM CaCl2 -2H20, and the pH was 
adjusted to 7.4 with 1 N HC1. A 12% BSA solution was prepared in this buffer and 
spiked with 0.5 \\M 11,12-EET and 0.5 uM 14,15-EET. Where indicated, tridecanoic 
acid (TA) was added at the same concentration as the internal standard. 
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5.2.4 EET extraction 
EETs were extracted from the plasma simulator as described in (164). Briefly. 
Millipore ultrafiltration tubes with a 10-kDa cutoff membrane were prewashed twice with 
400 \xL of water and centrifuged 12,000 rpm for 10 min to remove traces of nitrate. Then, 
400 |iL of the plasma simulator was loaded into the preconditioned ultrafiltration tube 
and centrifuged at 12,000 rpm for 20 min to remove BSA. The ultrafiltrate was collected 
and loaded into a Bondpack CI8 cartridge preconditioned with 2 mL of methanol 
followed by 4 mL of water. EETs were extracted with 1 mL of CHCI3/CH3OH (2:1) 
containing 0.1 mM TPP to quench any free-radical-induced lipid peroxidation (172). The 
sample was evaporated to dryness under a stream of nitrogen at atmospheric pressure, 
and the EETs were reconstituted in 300 U.L of the solvent of choice. 
5.2.5 ESI-MS/MS analysis of EETs 
EET analysis was carried out using a Micromass Quattro LC triple quadrupole 
mass spectrometer equipped with ESI source run by MassLynx software (Water Corp. 
Milford, MA). ESI-MS was carried out in negative-ion mode by direct infusion at a flow 
rate of 10 u.L/min. A capillary voltage of-3.0 kV, a cone voltage of-40 V, a source block 
temperature of 90 °C, a nebulizer gas flow of 30 L/h and a desolvation gas flow of 220 
L/h were maintained during all analysis. For samples in 100% ELO a desolvation 
temperature of 200 °C was used, and for samples in 100% ACN. 100% MeOH and 
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ACN/H20 (1:1), the desolvation temperature was set at 150 °C. Mass spectra in MS 
mode were scanned over the m/z range of 100-500 at a rate of 2 s/scan. In the MS/MS 
experiments, the deprotonated molecular ions [M-H]" of the EETs (m/z 319) were 
selected and fragmented by C1D using N2 gas and a collision energy range between 30 
and 50%. 
5.2.6 ESI-MS/MS analysis of 6KPGF l tx 
6KPGF]a analysis was carried out as described in (168). Briefly, ES1-MS was 
performed in negative-ion mode by direct infusion at 10 p:L/min into the Quattro LC 
triple quadrupole mass spectrometer. A capillary voltage of-3.0 kV, a cone voltage of -
60 V, a source block temperature of 90 °C, a nebulizer gas flow of 33 L/h, a desolvation 
gas flow of 253 L/h and a desolvation temperature of 150 °C were maintained during all 
analysis. In MS mode, spectra were scanned over the m/z range 50-400 at a rate of 2 
s/scan. In MS/MS mode, the deprotonated molecular ion [M-H]" of 6KPGFia (m/z 369) 
was selected and fragmented by CID using N2 gas with a collision energy range between 
40 and 60%. Samples were prepared in 10 mM triethylamine:methanol (1:1). A 




5.3.1 ESI-MS and ESI-MS/MS analysis of EETs 
EETs were studied by ESI-MS in negative-ion mode by direct infusion into the 
mass spectrometer. Both 11,12- and 14,15-EET exhibit the same [M-HT at m/z 319 
(Figure 5.4), but the fragmentation pattern observed by MS/MS was characteristic of each 
species (Figure 5.4, inserts). A set of common peaks were observed for both molecules at 
m/z 301, 275 and 257 corresponding to loss of H2O, CO2 and both H2O and CO2 from the 
[M-H]" ion (Figure 5.4) at the optimum collision energy of 40%. In addition, 11,12-EET 
exhibited fragment ions at m/z 167, 179 and 195. The last two peaks arise from 
fragmentation via opening of the epoxy ring on each side of the oxygen atom. 14,15-EET 
produced fragments at m/z 113, 205 and 219, with only one fragment related to the 
opening of the epoxy ring (m/z 219). In an equimolar mixture, the presence of both 
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Figure 5.4 Negative-ion ESI tandem mass spectra of EETs. (A) 0.25 uM 11,12-EET, (B) 0.25 \iM 
14,15-EET. Direct injection at 10 |iL/min in ACN. Instrument settings: source block temperature, 90 °C; 
capillary voltage, -3.0 kV; cone voltage, -40 V, collision gas, N2, collision energy, 40%. Inserts: 
fragmentation patterns for 11,12-EET and 14,15-EET. 
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Figure 5.5 Negative-ion ESI tandem mass spectrum of an equimolar EET mixture. Direct injection at 
10 uL/min on CAN of a solution of 0.25 |iM 11,12-EET and 0.25 ^M 14,15-EET was performed. [M-H]" 
observed at m/z 319 for both isomers and [M-H :0-H]\ [M-CO:-H]' and [M-H20- CO,-H]" at m/z 301, 275 
and 257, respectively. Peaks labelled O correspond to 14,15-EET fragments, and • correspond to 11,12-
EET fragments. Instrument settings: source block temperature, 90 °C; capillary voltage, -3.0 kV; cone 
voltase. -40 V, collision eas, N ;; collision enerav. 40%. 
5.3.2 Stability of EETs in different solvents 
The effects of solvent and storage on EET stability were assessed. For EET 
standards prepared in 100% ACN and stored overnight at -80 °C (Figure 5.6), a large 
decrease in the intensity of the [M-H]" ion at m/z 319 was observed. New signals not 
evident in the literature reports (155, 156) appeared at m/z 311, 325, 339, and 343. 
Figure 5.6 Negative-ion ESI mass spectra of EETs in 100% ACN after overnight storage at -80 °C. 
(A) 11,12-EET and (B) 14,15-EET standards. Direct injection of 0.25 uM EET at 10 uL/min. Instrument 
settings: source block temperature, 90 °C; capillary voltage, -3.0 kV; cone voltage, -40 V; scan range, 300-
350 m/z. 
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EET standards prepared in ACN:H20 (1:1) and stored overnight at -80 °C 
exhibited a strong [M-H]" peak (Figure 5.7). Weak signals were detected at m/z 311,312, 
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Figure 5.7 Negative-ion ESI mass spectra of EETs in ACN:H20 (1:1) after overnight storage at -80 
°C. (A) 11,12-EET and (B) 14,15-EET standards. Direct injection of 0.25 uM EET at 10 uL/min. 
Instrument settings: source block temperature, 90 °C; capillary voltage, -3.0 kV; cone voltage, -40 V; scan 
range, 300-350 m/z. 
EET standards prepared in 100% H20 and stored overnight at -80 °C (Figure 5.8) 
showed a base peak at m/z 328, with other possible peaks close to the noise level. 
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Figure 5.8 Negative-ion ESI mass spectra of EETs in 100% H20 after overnight storage at -80 °C. 
(A) 11,12-EET and (B) 14,15-EET standards. Direct injection of 0.25 uM EET at 10 uL/min. Instrument 
settings: source block temperature, 90 °C; capillary voltage, -3.0 kV; cone voltage, -40 V; scan range, 300-
350 m/z. 
Freshly prepared EETs in 100% MeOH (Figure 5.9) showed a strong [M-H]" ion 
at m/z 319. The peaks observed in ACN, ACN/H20, and H20 (Figures 5.6, 5.7, and 5.8, 
respectively) with m/z values greater than the [M-H]" ion are not observed in this case. 
Fragment ions corresponding to those seen in ACN:H20 (1:1) (Figure 5.4) are also seen 
in 100% MeOH (Figure 5.10). The best signal-to-noise ratio for the [M-H]" ion m/z 319 
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Figure 5.9 Negative-ion ESI mass spectra of EETs freshly prepared in 100% MeOH. (A) 11,12-EET 
and (B) 14,15-EET standards. Direct injection of 0.25 \iM EET at 10 uL/min. Instrument settings: source 
block temperature, 90 °C; capillary voltage, -3.0 kV; cone voltage, -40 V Note that the scan range for this 
spectra was m/z 100-320. 
Variation in storage time in the solvent systems studied (ACN, ACN/H2O, H20, 
MeOH) resulted in variation in the intensity of [M-H]\ the signal-to-noise ratio, and the 
fragmentation patterns. The results are summarized in Table 5.1. 
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Table 5.1 Effects of solvents and storage conditions on ions observed in the negative-ion ESI mass 







H , 0 MeOH 
0 min 
Signal-to-noise ratio 









Other peaks (m/z) 311.325.339.343 311.343 
24 h 
Signal-to-noise ratio 46.0 574 2.1 
Base peak (m/z) 311 319 327 
Other peaks (m/z) 319.325.339.343 311.325 
6 days 
Signal-to-noise ratio 45.: 482 
Base peak (m/z) 325 319 327 
Other peaks (m/z) 311,319,339,343 311,325 
11,12-EET and 14,15-EET (0.25 uM) were directly injected at 10 pL/min into the ESI source. Instrument 
settings: source block temperature, 90 °C; capillary voltage, -3.0 kV; cone voltage, -40 V; scan range, 300-
350 m/z. Data from Figures 5.6, 5.7, 5.8, and 5.9. 
The observation of peaks at higher m/z values than [M-H]~ or ions that do not 
exhibit the fragmentation patterns reported for EETs in the literature suggests the 
formation of adducts or the evolution of EET degradation products. For identification 
purposes. MS/MS analysis (Figure 5.11) was performed on the common ions at m/z 339, 
325. 311 (Table 5.1). These ions seem to be very stable since they were detected in old 
samples (stored at -80 °C for about a year, data not shown). The m/z 339 and 325 ions 
represent mass increases of 2Q u and 6 u. respectively, over the EET [M-H]" ion at m/z 
319, while m/z 311 ion represents a reduction of 8 u. After fragmentation with collision 
energies of 30 to 50%, all of these signals produced a fragment ion at m/z 183 (Figure 
5.10). 
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Figure 5.10 Negative-ion ESI mass spectra ions at m/z 339,325 and 311. (A) m/z 339 ion, (B) m/z 325 
ion, and (C) m/z 311 ion.. Direct injection of 0.25 (J.M EETs in ACN at 10 uL/min. Instrument settings: 
source block temperature, 90 °C; capillary voltage, -3.0 kV; cone voltage, -40 V, collision gas, N2; scan 
range, 100-350 m/z, collision energy 30-50%. 
The strong ion at m/z 327 observed for samples prepared in 100% H2O (Figure 5.8) 
exhibited a relatively strong peak at m/z 311 on MS/MS analysis (Figure 5.11). 
^ ^ k 4 , ^ f e f ^ * ^ . ^ 
Figure 5.11 Negative-ion ESI tandem mass spectrum of ion at m/z 327. Direct injection of 0.25 (iM 
11,12-EET and 14,15-EET in H20 at 10 pL/min. Instrument settings: source block temperature, 90 °C; 
capillary voltage, -3.0 kV; cone voltage, -40 V, collision gas, N : ; collision energy, 30-50%. 
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5.33 Dynamic range for EET analysis by ESI-MS 
Good linearity was observed for the ESI-MS calibration curves using the intensity 
of the [M-H]~ ion (m/z 319) in equimolar samples of 11,12-EET and 14,15-EET freshly 
prepared in 100% MeOH and immediately analyzed. A calibration curve was constructed 
using tridecanoic acid (TA), which exhibits a [M-HT ion at m/z 213, at a concentration of 
0.16 |lM as an internal standard. TA peaks (Figure 5.12) do not interfere with the 
fragmentation of the analytes, and TA has similar chemical properties to EETs (163). In 
Figure 5.13 a typical calibration curve for a 0 - 0.5 u,M mixture of 11.12-EET and 14,15-
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Figure 5.12 Negative-ion ESI mass spectrum of 0.16 u M tridecanoic acid in 100% M e O H . Direct 
injection at 10 uL/min. Instrument settings: source block temperature, 90 °C; capillary voltage. -3.0 kV; 
cone voltage, -40 V. [M-H]" at m/z 213. Insert: TA structure. Note that the scan range used to record this 
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Figure 5.13 EET calibration curve. Relative abundance of [M-H]" peak at m/z 319 vs total [EET]. 
Standards containing 0 - 0.5 uM mixtures of 11,12-EET and 14,15-EET with 0.16 uM TA as internal 
standard in 100% MeOH were directly infused into the ESI source. Experimental details are given in the 
legend of Figure 5.12. Equation, y = 1.8 (± 0.2) x + 0.03( ± 0.03) and correlation coefficient R2 is 0.9984 (± 
0.0042), n = 2. 
5.3.4 Recovery of EETs from artificial plasma 
Artificial plasma (Section 5.2.3) was spiked with of 0.5 |iM 11,12-EET and 0.5 
N,M 14,15-EET. After extraction using the procedure described in Section 5.2.4, no EET 
peaks were detected by ESI-MS. Scans performed between m/z 100-500 yielded spectra 
very similar to the spectrum of the solvent, 100% MeOH (data not shown). Thus, EETs 
cannot be recovered from plasma using the solid-phase extraction procedure outlined in 
Section 5.2.4. It is possible that EETs are retained by interaction with plasma proteins, 
such as BSA, present in the artificial plasma (Section 5.2.3). 
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5.3.5 ESI-MS and ESI-MS/MS analysis of 6KPGF,a 
6KPGFia was studied by ESI-MS in negative-ion mode by direct infusion into the 
mass spectrometer. The [M-H]~ ion at m/z 369 (Figure 5.14) was fragmented to give the 
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Figure 5.14 Negative-ion ESI mass spectrum of 6KPGFia. Direct injection of 475 nM 6KPGF]a at 10 
|iL/min in 10 mM triethylamine:methanol (1:1). Instrument settings: source block temperature. 90 °C; 
capillary voltage. -3.0 kV; cone voltage, -60 V, scan range, 50-400 m/z. [M-H]" at m/z 369. Insert: 
6KPGF|a structure. 
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Figure 5.15 Negative-ion ESI tandem mass spectrum of 475 nM 6KPGF l a . The experimental details 
are given in Figure 5.14 with the addition of collision gas N2 at a collision energy of 50%. 
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A set of weak peaks are observed at m/z 351, 333, 315, and 307 corresponding to 
the loss of H20, 2H20, 3H20 and H2O+CO2, respectively. Fragments at m/z 245 
(C17H25O), 205 (C4H21O), and 187 (C,4Hi9) have also been reported for PGI2, and result 
from the fragmentation of the carbohydrate backbone containing the 5C-ring (168). 
In a first attempt at quantitation, D4-6KPGF)a which contains D atoms at the 3, 
3', 4, and 4' positions, was used as an internal standard. The structure of D4-6KPGF]a as 
well as its ESI-MS spectrum is presented in Figure 5.16. 
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Figure 5.16 Negative-ion ESI mass spectrum of D4-6KPGF,„. Direct injection of 107 nM D4-
6KPGF,aat 10 uL/min in 10 mM triethylamine:methanol (1:1). Instrument settings: source block 
temperature, 90 °C; capillary voltage, -3.0 kV; cone voltage, -60 V, scan range, 50-400 m/z. [M-H]" at m/z 
373. Insert: 6KPGF,„ structure. 
The 6KPGFia calibration curve (Figure 5.17) exhibited good linearity when the 
relative abundance of the [M-H]" ion of 6KPGF,a at m/z 369 was plotted vs [6KPGF,a]. 
The calibration curve was used to confirm the concentration of a D4-6KPGFia sample, 
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which was found to be 106.39 nM, deviating from the theoretical value (106.8 nM) by 








Figure 5.17 6KPGF,a calibration curve of |M-H]~ peak abundance vs |6KPGF)a]. Plot represents a 
typical standard curve from 11 nM to 475 nM 6KPGF,a, with equation y = 3.5572 x + 449186 and 
correlation coefficient R2 = 0.9999. Standards solutions of 6KPGF)a in 10 mM triethylamine:methanol 
(1:1) were directly infused into the ESI source. Experimental details are given in the legend of Figure 5.15. 
5.4 Discussion 
The detection of 11,12-EET and 14,15-EET by ESI-MS is efficient with an LOD 
of 0.05 JIM. Also, these isomers can be easily identified by ES1-MS/MS since 
characteristic peaks for each EET are clearly distinguishable, as well as typical neutral 
losses of H2O and CO2 (Figures 5.4 and 5.5). EETs are extremely labile, easily air-
oxidized and light sensitive. Minimizing light exposure during sample preparation has to 
be assured. Therefore, working in indirect light as well minimum of contact with air by 
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the use of glass gas-tight syringes are necessary. Temperature is also an issue during 
manipulation; the stock solution must be kept below 10 °C at all times and samples are 
stored at -80 °C immediately after use. Time is also a limiting factor with EETs. Stock 
solutions degrade after a couple of days, and depending on the type of solvent, detection 
of the [M-H]" ion diminishes even during the course of a few hours. From the data in 
Table 5.1, the occurrence of degradation with time is evident. 
Detection of the [M-H]" ion decreases with time and the evolution of new peaks at 
higher m/z values was observed. In order to determine whether these peaks were 
generated from EET degradation or adduct formation, MS/MS analyses were performed. 
The MS/MS spectra (Figures 5.9 and 5.10) exhibit only weak signals in comparison with 
the MS/MS spectra obtained for the EET [M-H]" ion at m/z 319 (Figure 5.5). Also, the 
fragment ions formed from the unknown high mass ions are not equivalent to those 
obtained from freshly prepared EETs or to the fragments reported in the literature for 
EETs analyzed in ACN/water/methanoi/acetic acid or ACN/water/methanol/ammonium 
acetate at a ratio of 60:30:10:0.05 (155, 156). 
In an effort to explain the evolution of these new signals, possible mechanisms of 
EET degradation were considered. Hydrolysis of the epoxy ring (yielding 
dihydroxyeicosatrienoic acid, DHET) and/or hydrogenation of double bonds (yielding 
epoxyeicosanoic acid, EEA) represent possibilities (Figure 5.18). 
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Figure 5.18 Degradation products of 11,12-EET. Hydrogenation of double bonds generates 11,12-
epoxyeicosanoic acid (11,12-EEA). Hydrolysis of the epoxy ring generates 11,12-dihydroxyeicosatrienoic 
acid (11,12-DHET) 
EEAs and DHETs have been reported in RBCs (154). Since the experimental 
conditions used here (Sections 5.2.2, 5.2.4 and 4.2.5) are unlikely to convert EETs to 
EEAs or DHETs, these might have been present as an impurity in the commercial 
samples. 
In summary, [M-H]~ ions dominated the mass spectra of freshly prepared EETs in 
100% MeOH. Also, under these conditions, the abundance of the [M-H]" ion at m/z 319 
vs total EET concentration yielded a straight line with a correlation coefficient of 0.9984 
for mixtures of 11,12-EET and 14,15-EET. Unfortunately, EET recovery from the plasma 
simulator was not succesful. Therefore, application of this procedure to biological 
samples was not attempted. 
Detection and quantitation of 6KPGF]a was successful. Due to time constrains, 
application of this method to PGI2 extracted from plasma could not be performed. 
Nonetheless, this work is a starting point for future analytical measurements in biological 
matrices. The use of 6KPGFiaas a biomarker for prostaglandins and its deuterated 
analog D4-6KPGF|a appears to be promising for quantitation of PG1? by ESI-MS. 
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6.0 General conclusions and suggestions for future work 
6.1 Conclusions 
6.1.1 Chapters 2 and 3 
In Chapters 2 and 3, the effects of different stimuli on ATP release from RBCs 
were determined. Using a chemiluminescent detection method optimized for this study, it 
was confirmed that deaeration increases ATP release from RBCs (37, 135). It was also 
demonstrated that the incubation of RBCs with pharmacological concentrations of 
nitroglycerin results in a similar extracellular profile as nitrite. An initial increase in ATP 
release is followed by an attenuation of this effect within minutes. While the effects of 
nitroglycerin are delayed by ~30 s, the effects of nitrite are observed immediately. This 
difference is attributed to time required for nitroglycerin to release NO2" (50, 54). The 
subsequent attenuation of ATP release observed within 15 min in both cases could be 
considered as evidence of a negative feedback mechanism in the amplification of the 
vasodilatory signal. These seminal findings are summarized in Figure 3.5. Our 
observations constitute the first report of vasodilator release (ATP) following RBC 
stimulation by an endogenous NO donor (NO2") as well as by a pharmacological NO 
donor, nitroglycerin, and further suggest that RBC-derived ATP is a regulator of NO-
mediated vasoactivity in the circulation. 
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6.1.2 Chapter 4 
Activity assays on nitroglycerin-treated human RBCs showed that the drug exerts 
an inhibitory effect on the activity of GAPDH that is also concentration dependent. This 
confirms the previous findings in our group (M. Antonic et ai, unpublished results), 
which showed that nitroglycerin is a "suicide substrate" of GAPDH in vitro. GAPDH acts 
as an enzymatic activator of nitroglycerin to generate nitrite, which at the same time 
causes inactivation of the enzyme. This could partially account for the development of 
nitrate tolerance upon chronic exposure to the drug. 
6.1.3 Chapter 5 
Assessment of EET stability in various solvents was performed to establish the 
optimal conditions for LC-MS analysis. Freshly prepared samples in 100% MeOH 
proved to be the most stable. LC-MS/MS methods were optimized for the analysis and 
quantitation of EETs and PGl2-related metabolites with good sensitivity and selectivity. 
The method developed has the potential to be applied in the detection and quantitation of 
these vasodilators in human plasma. 
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6.2 Suggestions for future work 
I. The HPLC/UV methodology presented in Chapter 2 for the detection of 
extracellular ribonucleotides could be used to study the role of nucleases in the 
regulation of amplification of ATP-derived vasodilation signals, as well as for 
analyzing extracellular AMP/ATP and ADP/ATP levels related to stimulation by 
nitroglycerin, NO2", and other vasodilators. Synergistic or antagonistic effects of 
ATP and its related ribonucleoside adenosine, a known endogenous vasodilator, 
could also be assessed using this method. 
II. The development of an online/flow-through chemiluminescent detection system 
(8, 37, 173) to study instantaneous or short-term changes in the RBC ATP-release 
profile would provide more precise time resolution of ATP variation during and 
after stimulation with pharmacological agents or endogenous vasodilators. Such 
information would help to better understand the role of extracellular ATP in the 
propagation of vasodilatation and how this purinergic signaling pathway is 
controlled. 
III. The optimization of LC-UV/MS methodology for the detection and quantitation 
of nitroglycerin, 1,2- and 1,3-glyceryl dinitrates, and glyceryl mononitrate present 
in drug-treated RBCs, plasma, and intact blood vessels would help confirm the 
mechanisms by which the drug is activated in the vascular system. These 
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measurements, accompanied by the monitoring of NO2" levels, would also shed 
light on the mechanisms by which nitroglycerin exerts vasodilation. This still 
remains a mystery after more than 100 years of its use as a pharmacological 
treatment for ischemic diseases. 
IV. Isolation of GAPDH from human RBCs is of interest. The study of RBC GAPDH 
from healthy individuals and patients chronically exposed to nitroglycerin would 
help elucidate the role of this enzyme in the activation of nitroglycerin, and its 
possible involvement in the evolution of nitrate tolerance. 
V. The detection of EETs and PGI2 in plasma by LC-MS/MS should be further 
developed. Sensitive methods like ELISA are already available and these could be 
applied directly to plasma extracts to provide detection limits in the pg/mL range. 
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